Acute disease
MONDO:0020683Disease having a short and relatively severe course.
Also known as: acute disease, acute diseases, disease, acute
4495 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1834 trials in this tab.
-
Engineered immune cells take aim at Hard-to-Treat leukemia
⭐️ CURE ⭐️ Recruiting nowThis early-stage trial is testing an investigational therapy called B019, which uses a patient's own immune cells engineered to recognize and attack leukemia cells. The study focuses on people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard…
Phase: PHASE1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 00:00 UTC
-
Can a One-Two punch of CAR-T and lenalidomide beat tough leukemia?
⭐️ CURE ⭐️ Recruiting nowThis trial is testing whether combining anti-CD19 CAR-T cell therapy with the drug lenalidomide can safely and effectively treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatments. Participants…
Phase: PHASE1, PHASE2 • Sponsor: Vitebsk Regional Clinical Cancer Centre • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
⭐️ CURE ⭐️ Recruiting nowThis trial is testing an experimental therapy called CD22 CAR T cells in adults with certain types of B cell lymphomas that have come back or not responded to previous treatments. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack…
Phase: PHASE1 • Sponsor: Stanford University • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Can donor immune cells be engineered to fight blood cancer?
⭐️ CURE ⭐️ Recruiting nowThis trial tests a new type of cell therapy called KCAT19 for people aged 16 to 65 with advanced B-cell blood cancers that have relapsed or not responded to at least two prior treatments. The therapy uses immune cells from a donor's cord blood, which are modified to recognize and…
Phase: PHASE1 • Sponsor: University College, London • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can matching treatment to genetic risk beat relapsed childhood leukemia?
⭐️ CURE ⭐️ Recruiting nowThis trial is testing whether a treatment plan tailored to each child's genetic risk can improve outcomes for relapsed acute lymphoblastic leukemia. Children and young adults up to age 22 whose leukemia has returned in the bone marrow receive a combination of chemotherapy drugs, …
Phase: PHASE2 • Sponsor: Ho Joon Im • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
Personalized chemo dosing may boost survival in kids with High-Risk leukemia
⭐️ CURE ⭐️ Recruiting nowThis nationwide trial is testing whether adjusting chemotherapy intensity based on the amount of leukemia cells remaining after initial treatment (called minimal residual disease, or MRD) can improve outcomes for children and teens with high-risk acute lymphoblastic leukemia (ALL…
Phase: PHASE2 • Sponsor: Jae Wook Lee • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
Can a targeted drug combo beat the toughest childhood leukemia?
⭐️ CURE ⭐️ Recruiting nowThis phase 2 trial tests whether adding dasatinib and blinatumomab to standard chemotherapy can improve outcomes for children aged 1 to 19 with very high-risk acute lymphoblastic leukemia. The study focuses on patients with specific genetic markers or who did not respond to initi…
Phase: PHASE2 • Sponsor: Hyoung Jin Kang • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
Personalized chemo dosing may boost leukemia remission in kids
⭐️ CURE ⭐️ Recruiting nowThis trial tests whether using advanced genetic testing (NGS) to measure leftover cancer cells after initial treatment can help doctors tailor chemotherapy for children with standard-risk acute lymphoblastic leukemia. Around 116 children aged 1 to 10 will receive a standard chemo…
Phase: PHASE2 • Sponsor: Hee Young Ju • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
Personalized chemo and transplants aim to beat infant leukemia
⭐️ CURE ⭐️ Recruiting nowThis phase 2 trial tests whether adjusting chemotherapy and using stem cell transplants based on each infant's genetic profile can improve survival. Infants under one year old with newly diagnosed leukemia receive a risk-stratified treatment plan. The study aims to see if this pe…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
Can targeted drugs blinatumomab and venetoclax improve outcomes for childhood leukemia?
⭐️ CURE ⭐️ Recruiting nowThis large trial is testing whether adding the targeted drugs blinatumomab or venetoclax to standard chemotherapy can improve survival and reduce side effects in children with intermediate- or high-risk B-cell acute lymphoblastic leukemia (ALL). The study compares different sched…
Phase: PHASE2, PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: ⭐️ CURE ⭐️
Last updated Jul 25, 2026 00:00 UTC
-
Supercharged donor cells aim to stop leukemia return after transplant
⭐️ CURE ⭐️ Recruiting nowThis study tests a new approach to prevent leukemia from coming back after a stem cell transplant. It uses donor T cells that have been engineered to recognize and attack a specific target (HA-2) on leukemia cells. The trial enrolls adults with acute myeloid leukemia (AML) or mye…
Phase: PHASE3 • Sponsor: TScan Therapeutics, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart a deadly leukemia?
⭐️ CURE ⭐️ Recruiting nowThis trial is testing whether adding bortezomib to standard chemotherapy (CPX-351) can improve outcomes for people with a newly diagnosed, aggressive form of acute myeloid leukemia that has a TP53 mutation. The study aims to find a safe dose and see if the combination leads to mo…
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo aims to outperform standard therapy for Hard-to-Treat blood cancers
Disease control Recruiting nowThis phase 3 trial is testing whether a new drug, nemtabrutinib, combined with venetoclax works better than the current standard of venetoclax plus rituximab for people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 735 p…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New pill shows promise against tough blood cancers
Disease control Recruiting nowThis phase 2 study tests an oral drug called nemtabrutinib in about 490 people with blood cancers like chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenstrom's macroglobulinemia. The goal is to see if the drug can shrink tumors and control the cancer, while also chec…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can patients stop Anti-Rejection drugs sooner after transplant?
Disease control Recruiting nowThis study tests whether patients can safely stop the drug tacrolimus earlier than usual after a stem cell transplant. Tacrolimus is given to prevent graft-versus-host disease (GVHD), but newer methods have lowered GVHD risk. The trial will enroll 50 people with blood cancers and…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Heart patients may need only one blood thinner after balloon treatment, major trial tests
Disease control Recruiting nowThis study looks at whether taking just one blood thinner (a P2Y12 inhibitor) is as safe and effective as taking two blood thinners (dual antiplatelet therapy) for people with stable heart disease who have a drug-coated balloon procedure without a stent. About 2,170 adults will b…
Phase: NA • Sponsor: Gan Lijun • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New triple therapy aims to boost survival in frail AML patients
Disease control Recruiting nowThis phase 3 trial will test whether adding the drug quizartinib to the standard two-drug combination (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 376 people aged 18 and older who cannot receive intens…
Phase: PHASE3 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope in blood cancer battle: Next-Gen drug tested against standard therapy
Disease control Recruiting nowThis study tests whether a newer drug called pirtobrutinib works better than the current standard drug ibrutinib for people with chronic lymphocytic leukemia or small lymphocytic lymphoma. About 737 adults who need treatment for their cancer will be randomly assigned to receive o…
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New combo therapy aims to boost remission in IDH2-Mutated AML
Disease control Recruiting nowThis phase II trial tests whether adding enasidenib to standard ASTX727 and venetoclax improves remission rates in older adults (or younger unfit patients) with newly diagnosed IDH2-mutated acute myeloid leukemia (AML). About 93 participants will be randomly assigned to receive e…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control Recruiting nowThis early-phase trial is testing a new cell therapy called CD83 CAR T cells in 26 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy uses a patient's own immune cells, genetically modified to recognize and attack a protein (CD83…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New combo therapy aims to improve AML treatment for patients with specific gene changes
Disease control Recruiting nowThis early-phase trial tests whether adding a menin inhibitor (SNDX-5613) to standard chemotherapy can better control acute myeloid leukemia (AML) in people with certain gene changes (NPM1 or MLL). About 38 newly diagnosed adults will receive the combination to find the safest do…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope for young leukemia patients: targeted chemo combo aims to boost treatment success
Disease control Recruiting nowThis study is for adolescents and young adults (ages not specified) with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). Researchers want to see if a specific combination of chemotherapy drugs plus the immunotherapy blinatumomab helps more pat…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope for young AML patients: targeted drug combo tested in phase 2 trial
Disease control Recruiting nowThis study tests two different drug combinations for younger adults with a specific type of acute myeloid leukemia (CBF-AML). One group gets standard chemotherapy plus a targeted antibody, while the other gets the same chemotherapy plus a newer targeted pill. The goal is to see w…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New drug combo aims to keep childhood leukemia at bay after transplant
Disease control Recruiting nowThis phase 1 trial tests the safety and best dose of an oral drug called ASTX727 (a combination of cedazuridine and decitabine) along with filgrastim in children with high-risk acute myeloid leukemia (AML) that has returned or not responded to treatment. All participants have alr…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New combo therapy targets hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called UB-VV111 given with rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The main goal is to check the saf…
Phase: PHASE1 • Sponsor: Umoja Biopharma • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Heart failure emergency: which drug works best first?
Disease control Recruiting nowThis study tests whether opening blood vessels (vasodilation) or removing fluid (diuretics) is better for treating sudden fluid buildup in the lungs from heart failure. About 1,100 adults with severe shortness of breath and low oxygen levels will receive one of three treatments i…
Phase: PHASE4 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New drug aims to stop immune attack after stem cell transplants
Disease control Recruiting nowThis study tests a drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. Fifty adults with blood cancers like leukemia will receive six weekly doses of BPC200…
Phase: PHASE2 • Sponsor: BioPhoenix Co., Ltd. • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Scientists train immune cells to hunt down mutated blood cancers
Disease control Recruiting nowThis early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Personalized chemo boosts CAR T-Cell success in young leukemia patients
Disease control Recruiting nowThis study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can gentler therapy beat harsh chemo for tough leukemia?
Disease control Recruiting nowThis phase 3 trial tests whether less intense drug combinations can control relapsed or refractory acute myeloid leukemia (AML) as well as high-dose chemotherapy. About 339 adults whose AML has returned or not responded to initial treatment will be randomly assigned to either a l…
Phase: PHASE3 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for AML patients in india: drug combo aims for remission without intensive chemo
Disease control Recruiting nowThis study tests a combination of two drugs, venetoclax and azacitidine, in about 100 adults in India with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see if the combo can put the cancer into remissio…
Phase: PHASE4 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for kids with tough leukemia: experimental drug enters human testing
Disease control Recruiting nowThis early-stage study is testing an experimental drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check the drug's safety and how it moves through the body. Partici…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for AML patients: Triple-Drug combo targets Tough-to-Treat leukemia
Disease control Recruiting nowThis study tests whether adding pivekimab sunirine to the standard drugs venetoclax and azacitidine helps adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 660 participants will be randomly assigned to receive ei…
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can trained immune cells stop blood cancer relapse?
Disease control Recruiting nowThis trial tests whether giving patients special immune cells, called TAA-T, after a stem cell transplant can help prevent high-risk blood cancers like acute myeloid leukemia from coming back. The cells are designed to recognize three common tumor markers and attack any remaining…
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill aims to calm lupus skin flares in major trial
Disease control Recruiting nowThis study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for tough leukemia: MK-1045 takes on standard therapy
Disease control Recruiting nowThis study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new pill boost the power of an existing leukemia treatment?
Disease control Recruiting nowThis trial is testing whether an experimental drug called PBSS1113, taken as a pill alongside the standard medicine azacitidine, can help people with acute myeloid leukemia (AML) or a related condition called myelodysplastic syndrome (MDS). The study includes adults who have eith…
Phase: PHASE1, PHASE2 • Sponsor: Chaser Therapeutics, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a common antioxidant rescue failing livers?
Disease control Recruiting nowThis trial tests whether adding N-acetylcysteine (NAC) to standard care improves survival in adults with acute liver failure not caused by acetaminophen. Sixty-two patients will be randomly assigned to receive NAC or standard care alone. The study tracks survival at 28 days, hosp…
Phase: NA • Sponsor: King Edward Medical University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill aims to keep blood cancer away after transplant
Disease control Recruiting nowThis study tests a daily pill called olutasidenib given after a stem cell transplant to people with certain blood cancers (like AML or MDS) that have an IDH1 mutation. The goal is to see if the drug is safe and tolerable as maintenance therapy. About 31 participants will take the…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Fish oil treatment tested for kids with liver damage from IV nutrition
Disease control Recruiting nowThis study is testing the safety of Omegaven, a fish oil-based fat emulsion, in 40 children under 18 who have developed liver problems (cholestasis) from long-term IV nutrition. The main goal is to see how many children develop essential fatty acid deficiency during at least 8 we…
Sponsor: Fresenius Kabi • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for CLL patients with weak hearts: acalabrutinib under the microscope
Disease control Recruiting nowThis study tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have moderate to severe heart failure. Researchers want to see if acalabrutinib causes fewer heart-related side effects compared to other standard treatments. About 60 adults will t…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New targeted therapy aims to beat back childhood leukemia relapse
Disease control Recruiting nowThis study tests a drug called inotuzumab ozogamicin (Besponsa) against standard chemotherapy for children aged 1 to 17 with high-risk B-cell acute lymphoblastic leukemia that has returned after initial treatment. The goal is to see if the targeted drug can clear more cancer cell…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Plant-Based diet calm the immune system after a heart attack?
Disease control Recruiting nowThis trial investigates whether a five-week vegetarian diet can dampen the inflammatory response of the immune system in people who recently had a heart attack, as well as in healthy volunteers. Participants will follow a vegetarian diet for five weeks, then return to their usual…
Phase: NA • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill takes on hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests an experimental drug called EXS73565 in about 50 adults with certain blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, while also seeing if the d…
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Should High-Risk CLL patients start treatment early? major trial aims to find out
Disease control Recruiting nowThis phase 3 trial compares starting treatment with venetoclax and obinutuzumab right away versus waiting until symptoms appear in people with newly diagnosed, high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. About 247 participants will be randomly assigned t…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Engineered t cells target hidden leukemia cells in new trial
Disease control Recruiting nowThis phase I trial tests a new treatment for adults with acute myeloid leukemia (AML) who have minimal residual disease (MRD) — small amounts of cancer cells that remain after standard therapy. The treatment uses the patient's own T cells, genetically modified to recognize a prot…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New pill could transform leukemia treatment, phase 3 trial begins
Disease control Recruiting nowThis study tests a new oral drug, QTX-2101, combined with standard ATRA therapy for adults newly diagnosed with a low-risk form of acute promyelocytic leukemia (APL). The goal is to see if the oral capsule works as well as the current intravenous treatment. About 150 participants…
Phase: PHASE3 • Sponsor: Quetzal Therapeutics • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for rare leukemia: targeted pill tackles relapse
Disease control Recruiting nowThis study tests a pill called venetoclax for people whose hairy cell leukemia has returned after prior treatment. The drug blocks a protein that cancer cells need to survive. About 20 adults will take venetoclax to see if it shrinks tumors and improves blood counts, with the goa…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo aims for deeper remission in older leukemia patients
Disease control Recruiting nowThis phase II trial tests whether adding gilteritinib to the usual two-drug therapy (azacitidine and venetoclax) can help older or frail adults with a specific type of acute myeloid leukemia (FLT3-mutated) achieve deeper remission. About 147 participants will be randomly assigned…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for leukemia patients: targeted therapy aims to eliminate hidden cancer cells
Disease control Recruiting nowThis study tests whether a targeted drug called gemtuzumab ozogamicin can clear tiny amounts of leukemia that remain after initial treatment in adults with acute myeloid leukemia (AML). The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a chem…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Tough-to-Treat leukemia: multiple drug cocktails tested
Disease control Recruiting nowThis phase II trial tests several experimental drug combinations against the standard treatment for high-risk acute myeloid leukemia (AML) in patients aged 59 or younger. The goal is to see if newer regimens, including venetoclax and liposome formulations, can better shrink cance…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Kids' diarrhea: drug plus fluids tested
Disease control Recruiting nowThis study tests how the drug rifaximin (Xifaxan) works in children aged 6 to 11 with acute diarrhea likely caused by bacteria. Half the children get the drug plus oral rehydration therapy, the other half get rehydration alone. Researchers want to see if adding the drug helps dia…
Phase: PHASE4 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New program aims to help kids with leukemia take their daily chemo
Disease control Recruiting nowThis study tests MedSupport, a program designed to help families of children with acute lymphoblastic leukemia give their child daily oral chemotherapy at home. Missing even a few doses can raise the risk of cancer returning. The program uses a special pill bottle cap that tracks…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New shot may slash cholesterol right after a heart attack
Disease control Recruiting nowThis study tests whether starting inclisiran early during a hospital stay for a heart attack can lower bad cholesterol more than a placebo, when both are added to standard care. About 300 adults hospitalized for a heart attack will receive either inclisiran or a placebo shot at t…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a single dose of rituximab help hearts heal after a massive attack?
Disease control Recruiting nowThis study tests whether a single dose of rituximab, a drug that calms the immune system, can help the heart pump better six months after a severe type of heart attack called an anterior STEMI. About 372 adults who have just had such an attack will receive either rituximab or a p…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New CAR T-Cell therapy aims to stop High-Risk leukemia from returning
Disease control Recruiting nowThis Phase 2 trial is testing whether a CAR T-cell therapy called obecabtagene autoleucel (obe-cel) can help control newly diagnosed, high-risk B-cell acute lymphoblastic leukemia (ALL) after initial treatment. The study will enroll 30 adults with high-risk features who are in fi…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug combo trial targets blood cancers
Disease control Recruiting nowThis study tests a new drug called AZD0486, alone or with other cancer drugs, in people with B-cell blood cancers like certain lymphomas and leukemias. The goal is to see if it is safe and helps shrink or control the cancer. About 408 adults will take part in this early-phase tri…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Immune booster shot aims to speed recovery after cord blood transplant
Disease control Recruiting nowThis early-phase trial tests whether injecting special immune progenitor cells (HTLPs) can help the immune system recover faster after a cord blood transplant in adults with blood cancers. Ten participants will receive the injection alongside their transplant. The goal is to see …
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Massive new study aims to outsmart childhood leukemia
Disease control Recruiting nowThis study is testing a new, comprehensive treatment plan for children and young adults (ages 0-45) newly diagnosed with acute lymphoblastic leukemia (ALL). It combines the best approaches from previous successful treatments to improve survival and reduce side effects. The study …
Phase: PHASE3 • Sponsor: Mats Heyman • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for tough leukemia? early trial of debio 1562M begins
Disease control Recruiting nowThis early-phase trial is testing a new drug called Debio 1562M in about 134 people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The study first checks safety and finds the right dose, then looks at whether the drug can shrink the can…
Phase: PHASE1, PHASE2 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Old malaria drug may tame lupus skin flares
Disease control Recruiting nowThis study tests whether quinacrine, a medication originally used for malaria, can safely reduce skin rashes and sores in people with cutaneous lupus erythematosus (CLE). Participants receive either quinacrine or a placebo for 12 weeks, then all receive quinacrine for another 12 …
Phase: PHASE2 • Sponsor: Victoria Werth • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis phase 2 trial tests the drug mosunetuzumab in 30 people with chronic lymphocytic leukemia (CLL) who still have detectable cancer cells after at least six months of standard therapy. The goal is to see if the drug can clear those remaining cells and improve outcomes. Particip…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New combo therapy aims to tackle Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests whether adding a targeted drug (nemtabrutinib) to a personalized cell therapy (lisocabtagene maraleucel) can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to treatment. About 20 adults will rec…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New breathing machine approach aims to shield heart in lung failure patients
Disease control Recruiting nowThis study tests a breathing machine strategy that adjusts pressure based on lung measurements to protect the right side of the heart in 180 adults with moderate to severe lung failure from pneumonia. The goal is to see if this method reduces heart strain and complications compar…
Phase: NA • Sponsor: Beijing Chao Yang Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cocktail targets Hard-to-Treat leukemia
Disease control Recruiting nowThis early-phase trial tests whether combining three drugs—ruxolitinib, cladribine, and venetoclax—can control T-cell prolymphocytic leukemia (T-PLL) that has returned or not responded to prior treatment. The study will enroll 36 adults and primarily monitor safety and side effec…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Old drug, new hope: niclosamide tested for tough childhood leukemia
Disease control Recruiting nowThis early-phase trial tests niclosamide, a drug previously used for tapeworm infections, combined with standard chemotherapy in 16 children whose acute myeloid leukemia (AML) has returned or not responded to treatment. The main goal is to find a safe dose and check for side effe…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug cocktail aims to beat back tough blood cancers in young patients
Disease control Recruiting nowThis early-phase study tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) for teens and young adults aged 12 to 30 whose T-cell acute lymphoblastic leukemia or lymphoma has returned or not responded to prior treatment. The main goal is to c…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New triple therapy aims to wipe out hidden CLL cells
Disease control Recruiting nowThis study tests a combination of three drugs (zanubrutinib, obinutuzumab, and sonrotoclax) in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the treatment can make the cancer undetectable in the bloo…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for skin cancer patients with complex medical histories
Disease control Recruiting nowThis study tests a drug called cosibelimab in 80 people with advanced skin cancer who also have a kidney transplant or a blood cancer. The drug works by helping the immune system attack cancer cells. Researchers will check if the tumors shrink and monitor for side effects.
Phase: PHASE4 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New combo therapy aims to beat back relapsed leukemia after transplant
Disease control Recruiting nowThis phase 2 trial tests whether combining interferon-gamma (a protein that boosts the immune system) with donor immune cells can help patients whose acute myeloid leukemia or myelodysplastic syndromes have returned after a stem cell transplant. The study will enroll 45 adults an…
Phase: PHASE2 • Sponsor: Sawa Ito, MD • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a targeted drug boost chemo success in leukemia?
Disease control Recruiting nowThis phase II trial is testing whether adding the drug venetoclax to standard chemotherapy can improve remission rates in younger patients with intermediate-risk acute myeloid leukemia (AML). About 153 participants will receive either standard chemo or a combination with venetocl…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
CAR t cells aim to lock in remission for leukemia patients
Disease control Recruiting nowThis study tests a CAR T-cell therapy called obe-cel in adults with B-cell acute lymphoblastic leukemia (ALL) whose cancer is in complete remission with no detectable cancer cells. The goal is to see if obe-cel can prevent the cancer from coming back. About 40 participants will r…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a targeted drug boost transplant success for tough blood cancers?
Disease control Recruiting nowThis clinical trial is testing whether adding the drug venetoclax to standard chemotherapy before a stem cell transplant can improve outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study will enroll 324 participants and aims …
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug rocbrutinib takes on pirtobrutinib in blood cancer showdown
Disease control Recruiting nowThis study tests a new drug, rocbrutinib, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding to treatment. All participants have already tried a type of BTK inh…
Phase: PHASE3 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Genetically modified t cells take aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of immunotherapy for people with T-cell leukemia or lymphoma that has returned. The treatment involves taking a patient's own immune cells (or cells from a past stem cell donor), adding a special receptor that targets a protein called …
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a tailored Blood-Thinner combo prevent second heart attacks without causing bleeding?
Disease control Recruiting nowThis trial tests whether adding a low-dose blood thinner (rivaroxaban) to standard antiplatelet therapy for the first three months after a heart stent procedure can reduce the risk of future heart attacks, strokes, and other cardiovascular events in high-risk patients. Participan…
Phase: PHASE4 • Sponsor: China National Center for Cardiovascular Diseases • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combo aims to control rare blood cancer in High-Risk patients
Disease control Recruiting nowThis study tests a combination of two drugs, azacitidine and enasidenib, in people with a high-risk blood cancer called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to see if the drugs can stop cancer growth and improve outcomes. …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a tailored chemo cocktail outsmart a common leukemia?
Disease control Recruiting nowThis trial is testing whether a chemotherapy combination called HAD, given at intermediate doses, works better than the standard regimen for people with a specific genetic subtype of acute myeloid leukemia (AML) known as CEBPA double-mutated. The study enrolls adults aged 14 to 5…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New Antibody-Drug conjugate enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could an allergy pill mend hearts after an attack?
Disease control Recruiting nowThis trial tests whether fexofenadine, a common allergy medication, can help the heart heal better after a severe type of heart attack called STEMI. Participants will receive either fexofenadine or a placebo for six months, alongside standard care, after undergoing a procedure to…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Stem cells may supercharge CAR t for tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing whether adding a patient's own blood stem cells to standard CAR T-cell therapy is safe and doable for people with relapsed or refractory blood cancers like lymphoma, leukemia, and myeloma. Twenty participants will receive their own stem cells 10 …
Phase: PHASE1 • Sponsor: Joshua Sasine, MD, PhD • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for rare blood cancer: QUANTUM trial tests targeted therapy after transplant
Disease control Recruiting nowThis study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Heart stent showdown: which medicated device keeps arteries open best?
Disease control Recruiting nowThis study compares two medicated stents (tiny mesh tubes) used to open blocked heart arteries in people having a heart attack or unstable angina. About 2,100 participants will receive either a sirolimus-eluting stent (ihtDEStiny) or an everolimus-eluting stent (Xience). Research…
Phase: NA • Sponsor: Fundación EPIC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug HC-7366 tested for tough leukemia
Disease control Recruiting nowThis early-phase trial is testing a new drug called HC-7366 in 18 adults with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The main goal is to find a safe dose and check for side effects. Researchers hope this drug may offer a new option f…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can tailored fluid dosing tame pancreatitis?
Disease control Recruiting nowThis trial tests whether giving fluids based on real-time changes in stroke volume—a measure of how much blood the heart pumps—can improve outcomes in people with moderate to severe acute pancreatitis. Standard care uses a fixed weight-based amount, which can sometimes lead to fl…
Phase: NA • Sponsor: University of Southern California • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for blood cancer patients: experimental combo enters final testing phase
Disease control Recruiting nowThis study tests whether a new drug, sonrotoclax, combined with an antibody therapy works better than the current standard treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to prior therapy. About 630 par…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New CAR t-cell combo aims to control aggressive leukemia
Disease control Recruiting nowThis study tests a CAR T-cell drug called brexucabtagene autoleucel in 40 adults with B-cell acute lymphocytic leukemia that has come back or is hard to treat. Participants first receive standard chemotherapy drugs to reduce cancer, then get the CAR T-cells. The goal is to see if…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Diabetes drug metformin takes on leukemia gene
Disease control Recruiting nowThis early-phase study tests whether metformin, a common diabetes drug, can lower the level of a harmful gene mutation (DNMT3A R882) in 30 people with acute leukemia who are in remission. Participants will take metformin pills for 6 months, and researchers will check if the mutat…
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug aims to stop lung transplants from failing
Disease control Recruiting nowThis study tests whether the drug belumosudil can prevent chronic lung allograft dysfunction (CLAD) in people who have had a lung transplant and show signs of rejection or inflammation on a biopsy. About 234 participants will receive either belumosudil or a placebo for 52 weeks, …
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a pill help patients breathe easier with ARDS?
Disease control Recruiting nowThis study tests a drug called vadadustat in 1,100 hospitalized adults with acute respiratory distress syndrome (ARDS) caused by infection. Participants take either a low or high dose of vadadustat or a placebo daily for up to 14 days. The goal is to see if the drug reduces death…
Phase: PHASE2, PHASE3 • Sponsor: Paul Potnuru • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for kids with tough leukemia: targeted drugs added to chemo
Disease control Recruiting nowThis study tests whether adding dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs alongsi…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New combo therapy aims to boost survival in adult leukemia
Disease control Recruiting nowThis study is testing a powerful chemotherapy regimen originally designed for children, combined with the targeted drug venetoclax and immunotherapy, in adults aged 14 to 60 with a certain type of acute lymphoblastic leukemia (ALL). The goal is to see if this approach can achieve…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug cocktail aims to tackle tough blood cancers
Disease control Recruiting nowThis phase II trial is testing a combination of six chemotherapy drugs (clofarabine, etoposide, cyclophosphamide, liposomal vincristine, dexamethasone, and bortezomib) in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, or related cancers that have come back or…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug duo aims to stop kidney rejection in its tracks
Disease control Recruiting nowThis early-stage trial tests two drugs, carfilzomib and belatacept, in 25 kidney transplant recipients who have a type of rejection called antibody-mediated rejection. The goal is to see if the combination is safe and can reduce harmful antibodies or improve kidney function over …
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New dosing strategy aims to reduce dangerous side effect in blood cancer treatment
Disease control Recruiting nowThis study tests new ways to give the drug sonrotoclax to adults with chronic lymphocytic leukemia or mantle cell lymphoma. The goal is to find a dosing schedule that lowers the risk of tumor lysis syndrome, a serious side effect. About 258 participants will be enrolled to check …
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can targeted drug cocktails erase hidden leukemia cells?
Disease control Recruiting nowThis trial is testing whether combining various chemotherapy and targeted drugs can clear measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who are in remission but still have traces of leukemia cells. The study enrolls patients aged 14 and older with …
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug aims to keep leukemia at bay after first treatment
Disease control Recruiting nowThis Phase 3 trial is testing whether the drug surovatamig can help people with a specific type of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) stay in remission longer after their first round of treatment. About 420 participants will either receive suro…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can new drug cocktails beat back Hard-to-Treat leukemia?
Disease control Recruiting nowThis trial is testing several different drug combinations to find the best approach for people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. The study compares the effectiveness and safety of these salvage therapies, aiming to improve rem…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Allergy pill tested to protect heart attack survivors
Disease control Recruiting nowThis study is testing whether fexofenadine, a common allergy medication, can reduce the risk of serious heart and brain events in people who have recently had a heart attack. About 2,800 participants will receive either fexofenadine or a placebo for 24 months. The goal is to see …
Phase: PHASE3 • Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New device aims to save legs from clot emergencies
Disease control Recruiting nowThis study is testing a device called the Indigo Aspiration System to remove blood clots from leg arteries in people with acute limb ischemia, a condition where a clot suddenly blocks blood flow. About 300 participants will undergo a procedure where the device sucks out the clot.…
Sponsor: Penumbra Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New triple therapy offers hope for AML patients
Disease control Recruiting nowThis study tests a new combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as the first treatment for adults with newly diagnosed acute myeloid leukemia (AML). About 30 participants will receive this therapy, followed by standard chemotherapy and, for…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New antibody drug targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests an experimental drug called AZD5492 in people with B-cell cancers (like lymphoma or leukemia) that have come back or not responded to at least two prior treatments. The drug works by helping the body's T cells attack cancer cells. The trial will check safety, sid…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for Tough-to-Treat blood cancers: experimental pill takes on CLL and SLL
Disease control Recruiting nowThis Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has already been treated with two types of targeted therapy (BTK and BCL2 inhib…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Promising new combo therapy for infant leukemia shows potential
Disease control Recruiting nowThis study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Experimental drug TURALIO takes on tough childhood cancers in early trial
Disease control Recruiting nowThis early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Higher chemo dose may boost survival in rare leukemia subtype
Disease control Recruiting nowThis Phase 3 trial is testing whether a higher dose of the chemotherapy drug cytarabine, given with standard drugs, improves survival for people with acute myeloid leukemia (AML) that has a specific genetic change called RUNX1-RUNX1T1. The study will enroll 300 adults aged 14 to …
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a pill tackle Tough-to-Treat leukemia?
Disease control Recruiting nowThis study tests an experimental oral medicine called CHM-029 in adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments, and that carries specific genetic changes (NPM1 mutations or KMT2A/NUP98 rearrangements). The main goals are to fin…
Phase: PHASE1 • Sponsor: Charm Therapeutics • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Supercharged immune cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill nemtabrutinib takes on standard blood cancer drugs in major trial
Disease control Recruiting nowThis phase 3 trial is testing a new oral drug, nemtabrutinib, against two standard targeted therapies (ibrutinib or acalabrutinib) in 1,200 people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if nemtabrutinib works at least as well…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could less be more? new trial shortens leukemia drug course for seniors
Disease control Recruiting nowThis study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, works as well as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemot…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Donor immune cells take on tough T-Cell cancers in new trial
Disease control Recruiting nowThis phase 2 trial tests a one-time infusion of WU-CART-007, a CAR-T cell therapy made from healthy donor cells, in 125 people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to see if it can wipe ou…
Phase: PHASE2 • Sponsor: Allotera Therapeutics • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo aims to improve leukemia treatment before transplant
Disease control Recruiting nowThis study is for adults with a certain type of acute myeloid leukemia (AML) who are in remission and planning a stem cell transplant. It compares a combination of two drugs, venetoclax and azacitidine, against standard high-dose chemotherapy as a 'consolidation' step before the …
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for Tough-to-Treat blood cancers: phase 3 trial launches
Disease control Recruiting nowThis study compares a new drug, BGB-16673, to an existing one, pirtobrutinib, in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to prior treatment. About 500 adults will be randomly assigned to one of the tw…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a targeted pill boost chemo for tough blood cancer?
Disease control Recruiting nowThis Phase 3 trial tests whether adding the drug venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) or a related high-risk condition. About 650 participants aged 18 to 75 will receive either venetoclax or a placebo alongside chemo. …
Phase: PHASE3 • Sponsor: University of Ulm • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New device aims to wean ventilator patients faster
Disease control Recruiting nowThis study tests a temporary device that stimulates the diaphragm (the main breathing muscle) in ICU patients on breathing machines. The goal is to see if it helps patients breathe more on their own and recover from lung injury. About 30 adults with severe breathing failure will …
Phase: NA • Sponsor: Lungpacer Medical Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New pill could boost leukemia treatment for patients with specific gene changes
Disease control Recruiting nowThis phase 3 trial tests whether adding the drug bleximenib to standard chemotherapy helps adults with a certain genetic type of acute myeloid leukemia (AML). About 875 people will get either bleximenib or a placebo alongside chemo, then be followed for 4 years. The goal is to se…
Phase: PHASE3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo aims to tackle returning blood cancer
Disease control Recruiting nowThis phase 2 trial tests a combination of two drugs, acalabrutinib and venetoclax, in 80 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned after initial treatment. Participants must have responded well to their first ther…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Experimental CAR t therapy targets tough childhood leukemia
Disease control Recruiting nowThis early-phase trial is testing a new type of immune cell therapy called FOLR1 CAR T cells for children aged 6 and under with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy involves taking a child's own immune cells, modifying them in…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug karonudib tested in blood cancer patients
Disease control Recruiting nowThis early-phase trial tests the safety of a new drug called karonudib in up to 9 adults with blood cancers like leukemia who have no standard treatment options left. The study aims to find a safe dose and look for any signs that the drug works. It is too early to know if karonud…
Phase: PHASE1 • Sponsor: Thomas Helleday Foundation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New pill combo aims to outperform current standard in CLL
Disease control Recruiting nowThis phase 3 trial is testing whether a new combination of two oral drugs, sonrotoclax and zanubrutinib, works better than the current standard combination (venetoclax plus acalabrutinib) for people with untreated chronic lymphocytic leukemia (CLL). About 500 adults who have not …
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug pirtobrutinib tested for Long-Term safety in blood cancers
Disease control Recruiting nowThis study is checking the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with other drugs. About 150 adults who completed a previous pirtobrutinib study can join. They…
Phase: PHASE4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Gene therapy injection takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a pill shield the brain and kidneys during heart surgery?
Disease control Recruiting nowThis trial tests whether vericiguat, a drug that relaxes blood vessels, can protect the body during heart surgery. About 170 adults scheduled for open-heart surgery will receive either vericiguat or a placebo starting two days before the operation. Researchers will measure blood …
Phase: PHASE4 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo aims to keep High-Risk leukemia in remission before transplant
Disease control Recruiting nowThis study tests whether a combination of venetoclax and azacitidine works better than standard chemotherapy to keep high-risk acute myeloid leukemia (AML) from coming back before a stem cell transplant. About 216 adults who have already achieved remission after initial treatment…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug aims to wipe out cancer protein in Tough-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new oral drug, BGB-16673, designed to destroy a protein called BTK that helps certain blood cancers grow. The trial includes about 645 people with various B-cell cancers (like lymphoma and leukemia) that have come back or not responded to prior treatments. The …
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could lying on the stomach help infants breathe easier?
Disease control Recruiting nowThis trial investigates whether placing infants with severe acute respiratory distress syndrome (ARDS) on their stomachs (prone positioning) after surfactant treatment can improve their oxygen levels. The study involves 14 mechanically ventilated infants, comparing oxygenation an…
Phase: NA • Sponsor: Medical University of Vienna • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a tiny tube spare preterm babies from breathing machines?
Disease control Recruiting nowThis trial tests whether giving surfactant through a small tube while babies breathe with high-flow nasal cannula support can reduce the need for invasive ventilation. The study includes infants born 2-6 weeks early who have respiratory distress. Researchers will compare outcomes…
Phase: NA • Sponsor: King's College Hospital NHS Trust • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New inhaled therapy could help preterm infants breathe easier
Disease control Recruiting nowThis Phase 3 trial tests a new inhaled medication called APC-0101 in 520 premature babies born between 26 and 33 weeks who have respiratory distress syndrome. The drug is a surfactant that helps keep tiny air sacs in the lungs open. Some babies receive the active drug through a s…
Phase: PHASE3 • Sponsor: Aerogen Pharma Limited • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Zinc-Based compound fight cancer?
Disease control Recruiting nowThis trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…
Phase: PHASE1, PHASE2 • Sponsor: Vector Vitale LLC • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for Hard-to-Treat leukemia: Two-Drug combo enters human trials
Disease control Recruiting nowThis early-stage trial is testing two drugs, mosunetuzumab and venetoclax, in people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. Mosunetuzumab is given as a shot under the skin, and venetoclax is a daily pill. The study will chec…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Promising new combo aims to beat aggressive leukemia
Disease control Recruiting nowThis phase 2 trial is testing a combination of blinatumomab (an immune-boosting drug) with dasatinib or imatinib (targeted pills) and standard chemotherapy for people with a specific type of leukemia called Philadelphia chromosome-positive or Philadelphia chromosome-like B-ALL. T…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can an Oxygen-Boosting drug help when all else fails?
Disease control AVAILABLEThis program allows doctors to request NanO₂, an investigational drug that may help deliver oxygen to tissues, for patients with serious or life-threatening conditions like glioblastoma, respiratory distress, or ischemic stroke. It is for patients who have exhausted other treatme…
Sponsor: NuvOx LLC • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug combo aims to beat back relapsed leukemia
Disease control Recruiting nowThis study tests a new chemotherapy drug, L-Annamycin, combined with standard cytarabine in adults with acute myeloid leukemia (AML) that has come back or not responded to first treatment. About 312 participants will receive either the new drug combo or a placebo plus cytarabine.…
Phase: PHASE2, PHASE3 • Sponsor: Moleculin Biotech, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy aims to beat leukemia in young adults
Disease control Recruiting nowThis phase III trial is testing whether adding inotuzumab ozogamicin—a drug that targets cancer cells—to standard chemotherapy can improve outcomes for young adults (ages 18-39) newly diagnosed with B-cell acute lymphoblastic leukemia. About 310 participants will be enrolled. The…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo aims to beat standard CLL therapy in older patients
Disease control Recruiting nowThis Phase 3 trial compares a fixed-duration combination of zanubrutinib and sonrotoclax against continuous zanubrutinib alone in older patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The study will enroll 466 participants to see if the combo i…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Which dialysis dose saves more lives in the ICU? a trial seeks answers
Disease control Recruiting nowThis trial asks whether a lower or medium intensity of continuous kidney replacement therapy (dialysis) is better for critically ill patients with acute kidney injury. It will compare a low dose (12 mL/kg/hr) against a standard medium dose (25 mL/kg/hr) to see which is more effec…
Phase: PHASE2, PHASE3 • Sponsor: Jikei University School of Medicine • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Hospital-Made cancer fighters: new CAR-T trial for leukemia
Disease control Recruiting nowThis study is testing whether a personalized cell therapy called MB-CART19.1 can be manufactured right at the hospital for children and adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. The therapy uses the patient's own i…
Phase: NA • Sponsor: King Hussein Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New injection could stop pancreatitis from turning deadly
Disease control Recruiting nowThis study tests a single injection of a drug called RABI-767, given through a scope into the area around the pancreas, for people with predicted severe acute pancreatitis. About 36 participants will be randomly assigned to get the drug plus standard care or standard care alone. …
Phase: PHASE2 • Sponsor: Panafina, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New antibody therapy aims to stop chronic kidney transplant rejection
Disease control Recruiting nowThis trial tests a bispecific T-cell engager (BiTE) antibody in kidney transplant recipients who have chronic active antibody-mediated rejection (cAMR). The BiTE targets BCMA and CD3 to deplete harmful B cells and plasma cells that produce donor-specific antibodies. Researchers w…
Phase: PHASE4 • Sponsor: Turun Song • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can donor immune cells fight leukemia relapse after transplant?
Disease control Recruiting nowThis early-phase trial is testing whether infusing natural killer (NK) cells from a healthy donor, combined with low-dose interleukin-2 (IL-2), can safely help treat acute myeloid leukemia (AML) that has returned after a stem cell transplant. The study involves about 12 adults wi…
Phase: PHASE1 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis phase II trial is testing a combination of two targeted drugs, inotuzumab ozogamicin and blinatumomab, with or without ponatinib, for adults with a type of leukemia called B-ALL. The study includes newly diagnosed older adults and those whose cancer has returned or not respo…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New Bacteria-Based therapy tested for leukemia relapse prevention
Disease control Recruiting nowThis early-stage trial tests a new treatment called QUAIL-100, made from a live weakened bacteria, in children and young adults with high-risk leukemia or myelodysplastic syndrome who have already had a stem cell transplant. The main goal is to check safety and side effects. Only…
Phase: PHASE1 • Sponsor: Laguna Biotherapeutics, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for Tough-to-Treat blood cancers: NX-5948 trial opens
Disease control Recruiting nowThis study tests an experimental drug called NX-5948 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments, including BTK and BCL-2 inhibitors. The main goal is to see if the drug can shrink o…
Phase: PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody GEN3018 enters first human tests for tough blood cancers
Disease control Recruiting nowThis early-stage trial is testing a new antibody drug called GEN3018 in people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has come back or stopped responding to treatment. The main goal is to check safety and find the right dose. Up to 78 parti…
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a targeted pill boost standard therapy for hard-to-treat leukemia?
Disease control Recruiting nowThis phase 3 trial is testing whether adding revumenib, a drug that blocks a protein called menin, to the usual two-drug combination (azacitidine and venetoclax) can improve outcomes for adults newly diagnosed with acute myeloid leukemia (AML) that has a specific genetic change (…
Phase: PHASE3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for kids with relapsed leukemia: experimental drug combo enters safety trial
Disease control Recruiting nowThis early-stage study tests whether adding a new drug called revumenib to two standard chemotherapy drugs is safe for children and young adults whose acute myeloid leukemia (AML) has not responded to treatment or has returned. The study involves 24 participants and aims to find …
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Triple-Drug combo tame acute myeloid leukemia in frail patients?
Disease control Recruiting nowThis phase 2 trial is testing whether adding an experimental drug called MAX-40279 to the standard combination of venetoclax and azacitidine can help treat newly diagnosed acute myeloid leukemia (AML) in people who are not healthy enough for intensive chemotherapy. The study incl…
Phase: PHASE2 • Sponsor: Maxinovel Pty., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
A digital coach for the heart: app aims to keep risk factors in check after a heart attack
Disease control Recruiting nowThis trial tests whether a smartphone app called HeartCheck can help people who have recently survived a heart attack better manage their blood pressure, cholesterol, blood sugar, and smoking habits. The app provides education, reminders, and easy-to-understand goals to support m…
Phase: NA • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Radioactive antibody boosts transplant prep for tough leukemias
Disease control Recruiting nowThis early-phase trial tests whether adding a radioactive antibody (225Ac-DOTA-daratumumab) to standard chemotherapy and targeted radiation can safely improve the conditioning regimen before a donor stem cell transplant. The study includes 15 adults with high-risk acute myeloid l…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New combo pill attack aims to control blood cancers
Disease control Recruiting nowThis study tests two experimental drugs (rocbrutinib and lacutoclax) taken together to treat several types of blood cancers, including lymphoma and leukemia. The goal is to see if the combination is safe and can shrink or control the cancer. About 92 adults who have already tried…
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat blood cancer
Disease control Recruiting nowThis phase 2 trial tests lacutoclax, a daily pill that blocks a protein helping cancer cells survive, in 75 adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Participants take the drug until their disease worsens or side effects become…
Phase: PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Kidney shield: a simple care bundle may prevent organ failure after severe injury
Disease control Recruiting nowThis trial tests whether a set of five kidney-protecting measures — given early to severe trauma patients identified as high-risk by a urine test — can reduce the chance of acute kidney injury. About 500 adults with severe injuries will be randomly assigned to receive either the …
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a single antibody turn down the immune storm in ARDS?
Disease control Recruiting nowThis trial tests whether an antibody called IC14 can reduce dangerous lung inflammation in people with acute respiratory distress syndrome (ARDS), a severe condition where the lungs fill with fluid. Hospitalized patients on a ventilator receive either IC14 or a placebo, and resea…
Phase: PHASE2 • Sponsor: Implicit Bioscience • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a common antibiotic beat MRSA in kids? a trial puts TMP-SMX to the test
Disease control Recruiting nowThis trial compares two oral antibiotics—trimethoprim-sulfamethoxazole (TMP-SMX) and clindamycin—to see which works better for children with invasive MRSA infections, such as bone, joint, or deep tissue infections. About 100 children aged 60 days to 18 years will take one of the …
Phase: PHASE4 • Sponsor: Indiana University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?
Disease control Recruiting nowThis phase 3 trial is testing whether a combination of two targeted oral drugs—lisaftoclax and acalabrutinib—can work better than standard chemoimmunotherapy for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 344 particip…
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Immune clues may unlock better ECMO care for lung failure patients
Disease control Recruiting nowThis trial studies adults with moderate-to-severe acute respiratory distress syndrome (ARDS) who need ECMO life support. Researchers aim to classify patients into immune-based subtypes, understand why complications like kidney injury and bleeding occur, and develop a personalized…
Sponsor: Southeast University, China • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a standardized ECMO roadmap save more lives in ARDS?
Disease control Recruiting nowThis study investigates whether a standardized, full-course management pathway for ECMO can improve outcomes for adults with moderate-to-severe acute respiratory distress syndrome (ARDS). The pathway covers everything from deciding when to start ECMO through weaning and follow-up…
Phase: NA • Sponsor: Southeast University, China • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a new antiplatelet drug outperform clopidogrel after a heart attack?
Disease control Recruiting nowThis phase III trial tests whether vicagrel, an experimental antiplatelet drug, can prevent major heart-related events better than the standard drug clopidogrel in people with acute coronary syndrome (such as a heart attack or unstable angina) who are undergoing a stent procedure…
Phase: PHASE3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Ultrasound-Guided diuretic strategy may boost kidney recovery after cardiac surgery
Disease control Recruiting nowThis pilot trial tests whether using an ultrasound score (VeXUS) to guide fluid removal with diuretics can help kidneys recover in patients who develop acute kidney injury after cardiac surgery. About 40 participants will be randomly assigned to either VeXUS-guided fluid manageme…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Ancient herb, modern hope: ashwagandha compound tested to prevent deadly transplant complication
Disease control Recruiting nowThis trial tests whether a compound from the herb ashwagandha, called withaferin A, can help prevent graft-versus-host disease (GvHD) in people receiving a stem cell transplant for blood cancer. GvHD is a serious complication where donated immune cells attack the recipient's body…
Phase: PHASE1, PHASE2 • Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a Two-Pronged pill outsmart stubborn leukemia?
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug, HPB-092, in people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The drug is designed to block two proteins, FLT3 and IRAK4, that help leukemia cells grow and survive. The stud…
Phase: PHASE1 • Sponsor: Hangzhou Polymed Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
A simple urine test and a smart alert may help predict kidney failure in sick kids
Disease control Recruiting nowThis study tests whether adding a clinical decision support tool to the electronic medical record helps doctors use the furosemide stress test in critically ill children at high risk for acute kidney injury. The furosemide stress test measures how the kidneys respond to a diureti…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug aims to stop kidney transplant rejection
Disease control Recruiting nowThis study tests a new medicine called CID-103 in adults whose kidney transplants are being rejected by their immune system (antibody-mediated rejection). The trial has two parts: first, to find a safe dose, and second, to see if the drug can stop the rejection. About 58 people w…
Phase: PHASE1, PHASE2 • Sponsor: CASI pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Gut bacteria may tame pancreatitis — probiotic combo put to the test
Disease control Recruiting nowThis trial tests whether adding a specific probiotic (Bacillus subtilis and Enterococcus faecium) to standard lipid-lowering therapy can reduce triglyceride levels and inflammation in people hospitalized with pancreatitis caused by very high triglycerides. About 180 adults with m…
Phase: PHASE4 • Sponsor: Jianyin Zhou • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Spinal cord repair: could cell injections restore function in transverse myelitis?
Disease control Recruiting nowThis early-stage trial tests the safety of injecting Q-Cells, a type of human glial progenitor cell, directly into spinal cord lesions in people with transverse myelitis. The study enrolls up to 9 adults aged 18–70 who have had the condition for at least 3 months. Researchers wil…
Phase: PHASE1, PHASE2 • Sponsor: Q Therapeutics, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can an app save lives from overdose? philly trial aims to find out
Disease control Recruiting nowThis study tests whether a smartphone app called UnityPhilly can help bystanders quickly respond to opioid overdoses with naloxone. About 450 adults who live or work in three Philadelphia neighborhoods will use the app and receive training. Researchers will track how many overdos…
Phase: NA • Sponsor: Drexel University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New Triple-Drug strategy aims to boost remission in Hard-to-Treat leukemia
Disease control Recruiting nowThis phase 3 trial tests whether combining the targeted drug venetoclax with either a short course of decitabine or a modified DA regimen (daunorubicin and cytarabine) works better than the standard 3+7 DA regimen for adults newly diagnosed with acute myeloid leukemia. About 291 …
Phase: PHASE3 • Sponsor: The Second Affiliated Hospital of Kunming Medical University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Massive AML trial aims to find best chemo and transplant protection for younger patients
Disease control Recruiting nowThis study tests different chemotherapy doses and a drug to prevent graft-versus-host disease in adults aged 18 to 60 with newly diagnosed acute myeloid leukemia. Participants receive either idarubicin or daunorubicin during initial chemo, followed by high or intermediate doses o…
Phase: PHASE2, PHASE3 • Sponsor: University Hospital, Angers • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can the right dose and timing of steroids save more lives in ARDS?
Disease control Recruiting nowThis trial investigates whether different doses and durations of the corticosteroid dexamethasone improve outcomes for adults with acute respiratory distress syndrome (ARDS) who are on a ventilator. Participants are randomly assigned to receive either no steroids, a low or medium…
Phase: PHASE4 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a simple phosphate IV ease severe pancreatitis?
Disease control Recruiting nowThis study investigates whether giving phosphate through an IV can reduce the severity of acute pancreatitis in adults. Researchers want to know if low phosphate levels make the disease worse and if replenishing it helps. Participants receive either standard care or IV phosphate …
Phase: PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental drug combo aims to tackle tough lymphoma
Disease control Recruiting nowThis trial investigates whether combining two FDA-approved drugs, duvelisib and venetoclax, can safely and effectively treat peripheral T-cell lymphoma that has returned or stopped responding to prior therapies. The study enrolls adults who have tried at least two previous treatm…
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a 45-Minute talk after sepsis stop PTSD before it starts?
Disease control Recruiting nowThis study tests whether a single 45-minute psychiatric interview, given soon after ICU discharge for sepsis, can lower the risk of developing post-traumatic stress disorder (PTSD). Many ICU survivors face long-term mental health issues, but most hospitals lack early screening an…
Phase: NA • Sponsor: Barzilai Medical Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Ancient herb takes on transplant complication: Withaferin-A tested for Steroid-Resistant GVHD
Disease control Recruiting nowThis phase 2 trial tests whether a standardized extract from the ashwagandha plant, called Withaferin-A, can help people who develop graft-versus-host disease after a stem cell transplant and whose condition does not improve with steroids. The study enrolls 34 patients aged 12 an…
Phase: PHASE2 • Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Personalized immunotherapy strategies aim to improve outcomes for frail myeloma patients
Disease control Recruiting nowThis phase 3 trial is for people newly diagnosed with multiple myeloma who are not healthy enough for a stem cell transplant. After six months of standard treatment with daratumumab, lenalidomide, and dexamethasone, participants are assigned to different immunotherapy combination…
Phase: PHASE3 • Sponsor: University of Leeds • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Immune-Boosting drug aims to outsmart Hard-to-Treat blood cancers
Disease control Recruiting nowThis phase 1 trial tests a new drug called GTB-3650 for adults with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug is designed to connect natural killer cells—a type of immune cell—to cancer cel…
Phase: PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Waiting to clamp the cord: could 30 seconds save preterm babies?
Disease control Recruiting nowThis study compares delayed cord clamping (waiting at least 30 seconds after birth) with immediate clamping in preterm infants born between 32 and 37 weeks. The goal is to see if the extra time improves early health outcomes such as breathing, anemia risk, and survival. Researche…
Phase: NA • Sponsor: Faculty of Medicine of Tunis • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat childhood leukemia
Disease control Recruiting nowThis trial investigates a personalized cell therapy called CAR-T for children and young adults (ages 5–50) with B-cell acute lymphoblastic leukemia that has relapsed or not responded to standard treatment. The therapy involves collecting a patient's own immune cells, engineering …
Phase: EARLY_PHASE1 • Sponsor: Dr. Zaineb Akram • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Drainage showdown: which Non-Surgical route best treats gallbladder attacks?
Disease control Recruiting nowThis trial compares two non-surgical drainage methods for acute cholecystitis (gallbladder inflammation) in people who are too sick for surgery. One method uses a tube through the skin, the other uses an endoscope to place a stent. Researchers will track complications, repeat pro…
Phase: NA • Sponsor: Orlando Health, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Simple arm cuff before angioplasty may boost heart attack recovery
Disease control Recruiting nowThis trial tests whether a noninvasive procedure called RE-START, which uses a blood pressure cuff to temporarily stop blood flow in the arm, can improve blood flow in the heart's arteries before standard angioplasty in people having a severe heart attack (STEMI). The study invol…
Sponsor: Firat University • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Suction device may improve outcomes in heart attack patients with large clots
Disease control Recruiting nowThis trial tests whether using a suction catheter to remove large blood clots before placing a stent improves outcomes in people having a severe heart attack (STEMI). Participants must have a large clot visible on angiography. Half receive standard stent placement alone, and half…
Phase: PHASE2, PHASE3 • Sponsor: Oxford University Hospitals NHS Trust • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Heart healing from the inside out: resilience training may boost recovery after cardiac events
Disease control Recruiting nowThis study tests whether adding resilience training—a mix of group therapy and relaxation exercises—to standard rehabilitation helps people recover from Takotsubo cardiomyopathy (broken heart syndrome) or a recent heart attack. Participants attend two group therapy sessions and t…
Phase: NA • Sponsor: Pensionsversicherungsanstalt • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Double-Barreled attack: Gene-Edited stem cells and CAR T-Cells take on tough leukemia
Disease control Recruiting nowThis trial tests a two-part treatment for people with acute myeloid leukemia (AML) that has not responded to standard therapy. First, patients receive a stem cell transplant from a healthy donor, but the stem cells are gene-edited to hide from the second treatment: specially engi…
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New antibody may offer safer shield against transplant complications
Disease control Recruiting nowThis phase 3 trial compares an anti-CD25 monoclonal antibody (daclizumab) with methotrexate for preventing acute graft-versus-host disease (GVHD) in people with blood cancers receiving a half-matched stem cell transplant. GVHD is a serious complication where donor immune cells at…
Phase: PHASE3 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Combination drug approach aims to tame immune attack after stem cell transplant
Disease control Recruiting nowThis trial tests whether adding leflunomide to standard steroid therapy can safely control acute graft-versus-host disease (aGVHD) in people who have had a stem cell transplant for blood cancer. aGVHD occurs when donor immune cells attack the patient's own body. Leflunomide and s…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New aspiration sheath may protect kidneys during stone surgery
Disease control Recruiting nowThis trial compares a new aspiration-enabled access sheath to a conventional one during retrograde intrarenal surgery (RIRS) for kidney stones. The new sheath continuously removes irrigation fluid to control pressure inside the kidney, potentially reducing temporary kidney injury…
Phase: NA • Sponsor: Namik Kemal University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New combo therapy for CLL tested in Real-World settings
Disease control Recruiting nowThis study is looking at how well a combination of two drugs, ibrutinib and venetoclax, works for people with chronic lymphocytic leukemia (CLL) when used in everyday medical practice. Researchers will follow 60 patients who are already scheduled to receive this treatment to see …
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New transplant recipe aims to tame Graft-Versus-Host disease
Disease control Recruiting nowThis study tests a stem cell transplant using a reduced-intensity conditioning regimen (lower doses of chemotherapy and radiation) followed by a donor stem cell infusion. The goal is to treat various blood cancers and blood disorders while lowering the risk of graft-versus-host d…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New BTK blocker aims to outsmart drug resistance in elderly CLL patients
Disease control Recruiting nowThis phase 2 trial tests a drug called pirtobrutinib in people aged 75 and older with untreated chronic lymphocytic leukemia (CLL). Pirtobrutinib is a next-generation BTK inhibitor designed to block cancer growth signals, potentially working even when other similar drugs stop bei…
Phase: PHASE2 • Sponsor: Jennifer Woyach • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New endoscopic drainage may spare elderly patients from gallbladder surgery
Disease control Recruiting nowThis study compares two treatments for acute cholecystitis (inflamed gallbladder) in patients aged 75 and older. One is the standard laparoscopic surgery to remove the gallbladder. The other is a newer, less invasive procedure called EUS-guided gallbladder drainage, where a small…
Phase: NA • Sponsor: Oulu University Hospital • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a shorter course of blood thinners be safer after a heart attack?
Disease control Recruiting nowThis study looks at people who have had a severe type of heart attack called STEMI. It compares a shorter course (about one month) of two blood thinners followed by just one drug (prasugrel) for a year, versus the standard one-year regimen of two blood thinners. The goal is to se…
Phase: PHASE4 • Sponsor: Research Maatschap Cardiologen Rotterdam Zuid • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immune cell injection takes on Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage trial tests an experimental cell therapy called IBR733 for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. The therapy involves giving immune cells by vein in repeated cycles. The main goals are to check safety, …
Phase: PHASE1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered immune cells take aim at Tough-to-Treat blood cancers
Disease control Recruiting nowThis trial investigates CRC01, a therapy made from a patient's own immune cells that are genetically modified to recognize and attack cancer cells. It is for adults with large B-cell lymphoma or B-cell acute lymphoblastic leukemia that has returned or not responded to previous tr…
Phase: PHASE1, PHASE2 • Sponsor: Curocell Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a diabetes drug shield kidneys from autoimmune attack?
Disease control Recruiting nowThis trial investigates whether pioglitazone, a drug used for diabetes, can help protect the kidneys in people with ANCA-associated vasculitis—a rare autoimmune disease that causes inflammation of blood vessels, often damaging the kidneys. Participants receive either pioglitazone…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail aims to beat back stubborn leukemia
Disease control Recruiting nowThis study tests a combination of four drugs, called CLAG-GO, in adults whose acute myeloid leukemia (AML) has not responded to standard treatment or has come back after remission. Participants receive the drugs during a hospital stay, and if the cancer goes into remission, they …
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Combination therapy aims to keep leukemia in check after transplant
Disease control Recruiting nowThis study tests whether adding the drug blinatumomab along with a low dose of donor immune cells (called donor lymphocyte infusion) can help prevent relapse in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already had a stem cell transplant. The trea…
Phase: PHASE1 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Experimental triple therapy aims to tame leukemia without intensive chemo
Disease control Recruiting nowThis phase I trial tests whether adding the experimental drug iadademstat to two standard leukemia medications (azacitidine and venetoclax) is safe and tolerable for adults with newly diagnosed acute myeloid leukemia (AML) who cannot undergo intensive chemotherapy. Iadademstat bl…
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo aims to tame immune attack after stem cell transplants
Disease control Recruiting nowThis phase 2 trial tests whether adding vedolizumab to standard drugs (cyclophosphamide and tacrolimus) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia and myelodysplastic syndrome. GVHD occurs when donor immu…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Light-Based therapy may tame kidney transplant rejection
Disease control Recruiting nowThis study looks at whether a treatment called extracorporeal photopheresis can help kidney transplant recipients whose bodies are rejecting the new organ. The treatment involves filtering the patient's blood, treating it with a light-activated drug, and returning it to the body.…
Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can custom ventilation save more ARDS lungs?
Disease control Recruiting nowThis study tests whether a personalized breathing machine strategy can improve survival in people with acute respiratory distress syndrome (ARDS), a severe lung condition. About 1,100 adults on ventilators will be randomly assigned to either standard care or a precision approach …
Phase: PHASE3 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a common bile acid pill shield kidneys during cancer surgery?
Disease control Recruiting nowThis trial investigates whether ursodeoxycholic acid (UDCA), a bile acid medication, can protect kidney function in adults undergoing partial nephrectomy for kidney cancer. During surgery, blood flow to the kidney is temporarily stopped, which can cause injury. Participants take …
Phase: PHASE2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New plavix rival enters human testing
Disease control Recruiting nowThis early-stage trial compares a new investigational drug, CG-0255, to the established blood thinner Plavix in 136 healthy adults aged 18-55. The goal is to see if CG-0255 is processed by the body similarly to Plavix and has the same effect on preventing blood clots. Participant…
Phase: PHASE1 • Sponsor: Shanghai CureGene Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo aims to beat High-Risk leukemia and MDS
Disease control Recruiting nowThis phase II trial tests whether adding targeted total marrow irradiation to standard chemotherapy before a stem cell transplant can improve outcomes for people with high-risk acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndromes. The study will enroll 3…
Phase: PHASE2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New care plan aims to keep kidney patients out of the hospital
Disease control Recruiting nowThis study tests whether a personalized care plan at hospital discharge helps people who survived acute kidney injury recover better. Depending on their risk level, patients get education, a primary care visit, or specialist monitoring. The goal is to see if this approach increas…
Phase: NA • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo aims to shorten CLL treatment
Disease control Recruiting nowThis phase 2 trial tests two oral drugs, zanubrutinib and sonrotoclax, in 24 people with untreated high-risk CLL/SLL. The goal is to see if a time-limited treatment guided by minimal residual disease (MRD) can achieve deep remission. Participants take the drugs for up to 27 cycle…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental immune therapy aims to reduce deaths in severe pneumonia
Disease control Recruiting nowThis study tests whether a single dose of an experimental immune cell therapy called agenT-797, given alongside standard care, can lower the risk of death in adults with severe pneumonia and breathing failure. About 90 people in intensive care will receive either agenT-797 or a p…
Phase: PHASE2 • Sponsor: MiNK Therapeutics • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control Recruiting nowThis study tests a new type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CD7. It includes people with several blood cancers, such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia. The goal is…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can one infusion speed recovery from sickle cell lung crisis?
Disease control Recruiting nowThis study tests whether a single dose of tocilizumab, an anti-inflammatory drug, can help children and adults with sickle cell disease recover faster from acute chest syndrome—a serious lung condition. Participants receive either the drug or a placebo, and researchers measure ho…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can 'Supercharged' donor cells beat viruses that drugs Can't?
Disease control Recruiting nowThis study tests whether giving patients special donor immune cells (called CD45RA-depleted DLI) can treat viral infections that persist after a stem cell transplant. The trial involves 30 participants who have not improved with standard antiviral drugs. Researchers will measure …
Phase: PHASE1, PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo aims to put CLL into deep remission and let patients stop treatment
Disease control Recruiting nowThis phase 2 trial is testing two targeted drugs, zanubrutinib and obinutuzumab, in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if starting obinutuzumab at different times leads to deep remission wher…
Phase: PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to outsmart resistant leukemia
Disease control Recruiting nowThis early-phase trial is testing whether combining two oral drugs, eltanexor and venetoclax, is safe and effective for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study will enroll 60 adult…
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at leukemia that evades standard therapy
Disease control Recruiting nowThis trial investigates a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia (B-ALL) whose cancer has stopped responding to anti-CD19 treatment. The therapy uses a patient's own immune cells, modified to target several other markers on leukemia cel…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to wipe out leukemia cells for good
Disease control Recruiting nowThis early-stage trial tests a combination therapy for B-cell acute lymphoblastic leukemia (B-ALL). It uses specially engineered immune cells (CAR-T cells and CTLs) followed by a dendritic cell vaccine to target multiple cancer markers. The goal is to achieve a very deep remissio…
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a drug help AML patients fight Chemo-Related anemia?
Disease control Recruiting nowThis trial investigates whether luspatercept can treat anemia caused by chemotherapy in adults with low-risk acute myeloid leukemia (AML). Participants receive luspatercept injections after chemotherapy, and researchers monitor hemoglobin levels and safety. The study aims to find…
Phase: PHASE1, PHASE2 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Double-Barreled immune attack aims to wipe out T-ALL
Disease control Recruiting nowThis early-phase trial tests a two-part immune therapy for people with T-cell acute lymphoblastic leukemia (T-ALL). First, patients receive specially engineered T cells (CAR-T) that target multiple markers on leukemia cells. Then, they get a booster with cytotoxic T cells and a d…
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy targets tough leukemia in older patients
Disease control Recruiting nowThis early-phase trial is testing whether adding the drug daratumumab to standard chemotherapy can help adults aged 60 and older with a high-risk form of acute myeloid leukemia (AML). The main goal is to find the safest dose of daratumumab when given alongside chemotherapy. The s…
Phase: PHASE1 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control Recruiting nowThis phase 1 trial tests a new type of immunotherapy called universal CAR T cells in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The cells are engineered to recognize and attack leukemia cells by targeting four different proteins (CL…
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Rapid heart pump upgrade may save lives in shock
Disease control Recruiting nowThis study tests whether quickly upgrading from a standard heart pump (Impella CP) to a more powerful one (Impella 5.5) within 24 hours after a heart attack improves outcomes for people in cardiogenic shock. The trial will enroll 115 adults aged 18-77 who have had a heart attack …
Sponsor: University Hospital of Cologne • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called ICG415 CAR-T cells for adults with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack leukemia cel…
Phase: PHASE1 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug aims to wake up immune system against Hard-to-Treat leukemia
Disease control Recruiting nowThis early-phase trial tests a drug called CRD3874-SI, which activates the STING pathway to boost the immune system's ability to fight cancer cells. It is for people with acute myeloid leukemia (AML) that has returned or not responded to previous treatments. The main goal is to f…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Double strike: engineered immune cells and targeted pill take on tough leukemia
Disease control Recruiting nowThis study tests a new approach for people newly diagnosed with a specific, aggressive leukemia (Ph+ ALL). It combines a single infusion of specially engineered immune cells (CAR-T cells) with a daily targeted pill (olverembatinib). The goal is to see if this powerful one-two pun…
Phase: EARLY_PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Kidney transplant trial tests which drug better prevents rejection
Disease control Recruiting nowThis phase 3 trial compares two induction therapies—rabbit anti-thymocyte globulin (rATG) and basiliximab—in 244 sensitized kidney transplant recipients who do not have pre-existing donor-specific antibodies. The goal is to see which drug better prevents biopsy-proven acute rejec…
Phase: PHASE3 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to keep leukemia in remission after transplant
Disease control Recruiting nowThis early-phase trial is testing the drug asciminib as a maintenance treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who have already received a stem cell transplant or CAR T-cell therapy. The goal is to see if asciminib is safe …
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Daily pill aims to improve bladder function in children with spinal conditions
Disease control Recruiting nowThis study tests a daily pill called vibegron to see if it safely improves bladder control in children aged 2 to 18 with neurogenic detrusor overactivity (NDO), a condition where the bladder contracts too often due to nerve damage. Participants must already use a catheter to empt…
Phase: PHASE2, PHASE3 • Sponsor: Urovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets rare gene mutation in Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests an oral drug called AG-120 in people with advanced blood cancers, like acute myeloid leukemia, that have a specific IDH1 mutation. The study aims to find the safest dose and see if the drug can control the disease. About 291 participants will take the…
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a Two-Drug cocktail replace triple therapy for heart stent patients?
Disease control Recruiting nowThis study tests whether a two-drug combination of dabigatran and ticagrelor can lower bleeding risk compared to the standard three-drug therapy (dabigatran, clopidogrel, and aspirin) in people with atrial fibrillation who have had a heart stent after a heart attack. About 1,200 …
Phase: PHASE4 • Sponsor: Medical University of Gdansk • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Banked immune cells show promise against Life-Threatening viruses in transplant patients
Disease control Recruiting nowThis early-phase study tests whether specially trained immune cells from healthy donors can safely treat viral infections (EBV, CMV, adenovirus, BK virus) in patients who have had a stem cell transplant or certain CAR-T therapy. These infections can be life-threatening when the i…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental 'Storm Stopper' therapy tested for COVID-19, flu, and RSV
Disease control Recruiting nowThis early-stage trial tests a new drug called PRS CK STORM, made from a mix of immune and fat cells, to see if it can safely calm the 'cytokine storm'—a dangerous overreaction of the immune system—in people with severe lung infections from COVID-19, flu, or RSV. The study will e…
Phase: PHASE1, PHASE2 • Sponsor: PEACHES BIOTECH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental immune therapy takes on tough lymphomas
Disease control Recruiting nowThis early-phase trial is testing a new cell therapy called TBI-2001 for people with certain blood cancers (B-cell lymphoma, CLL, SLL) that have come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to recognize and a…
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo aims to halt artery plaque after heart attacks
Disease control Recruiting nowThis study tests whether adding evolocumab, a cholesterol-lowering drug, to standard care can slow or stop plaque buildup in heart arteries after a heart attack. About 233 adults aged 40-75 who recently had a heart attack or unstable angina will receive either evolocumab plus sta…
Phase: PHASE4 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy targets Brain-Attacking antibodies in severe encephalitis
Disease control Recruiting nowThis study tests whether combining two drugs—ofatumumab and daratumumab—can safely and effectively treat people with severe anti-NMDAR autoimmune encephalitis, a condition where the immune system attacks the brain. The drugs aim to eliminate the harmful immune cells producing the…
Phase: PHASE3 • Sponsor: The First People's Hospital of Changzhou • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called IC19/1563 for people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recogn…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Which drain first? trial tests best emergency move for blocked kidney
Disease control Recruiting nowThis study looks at people with a sudden kidney blockage from a stone in their only working kidney. Doctors will randomly use either a tube placed through the bladder or one through the back to drain urine. The goal is to see which method helps kidney function recover better and …
Phase: NA • Sponsor: Beni-Suef University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Home rehab program aims to keep heart patients out of hospital
Disease control Recruiting nowThis study tests whether a 4-month structured telerehabilitation program, delivered via video calls and an app, can reduce deaths and hospital readmissions in heart patients who have Post-Intensive Care Syndrome (PICS). About 326 adults aged 30-75 who were in the ICU for at least…
Phase: NA • Sponsor: Fondazione Don Carlo Gnocchi Onlus • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New transplant method aims to cut dangerous side effects in blood cancer patients
Disease control Recruiting nowThis study tests a stem cell transplant method that removes certain immune cells (T-cells and B-cells) from the donor cells. The goal is to reduce graft-versus-host disease, a serious complication where donor cells attack the patient's body. The trial includes 20 children and you…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental CAR-T therapy takes on tough leukemia
Disease control Recruiting nowThis early-stage trial is testing a new type of CAR-T cell therapy, called CT0890B, for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses donor-derived immune cells that are engineered to target a protein called NKG2DL on …
Phase: PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a common antibiotic slash deaths from brain TB?
Disease control Recruiting nowThis phase 2 trial tests whether adding the antibiotic doxycycline to standard treatment can reduce deaths and severe brain damage in adults with tuberculosis of the brain or its lining. About 200 participants will receive either doxycycline or a placebo for 8 weeks, alongside us…
Phase: PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Poop pills may tame deadly transplant complication
Disease control Recruiting nowThis study tests whether fecal microbiota transplantation (FMT) can safely treat gut graft-versus-host disease (GVHD), a serious complication after stem cell transplants. Researchers will track changes in stool frequency and volume in 50 participants aged 10 to 60. The goal is to…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for heart attack patients: can a common blood thinner prevent strokes?
Disease control Recruiting nowThis study tests whether adding the blood thinner rivaroxaban (Xarelto) to standard care helps dissolve dangerous blood clots in the heart after a major heart attack. Researchers will track 320 participants to see if the drug reduces strokes and other complications. The goal is t…
Phase: NA • Sponsor: Jilin University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for japanese AML patients: experimental drug ziftomenib enters trial
Disease control Recruiting nowThis study tests an experimental drug called ziftomenib in 6 Japanese adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The drug is taken as a pill once daily. The goal is to see if it can help control the disease and how…
Phase: PHASE2 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can pressurized oxygen boost stem cell transplants?
Disease control Recruiting nowThis early-phase study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard stem cell transplant preparation is safe and helps recovery. It involves 24 adults with various blood cancers, such as leukemia and myelofibrosis. Th…
Phase: EARLY_PHASE1 • Sponsor: Omar Aljitawi • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Triple-Target CAR T-Cells offer new hope for tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New device aims to catch surgical debris, prevent stroke and kidney damage
Disease control Recruiting nowThis trial tests a special cannula that captures debris during high-risk heart valve surgery. The goal is to see if it reduces the chance of stroke, kidney injury, and delirium. About 842 patients aged 60 and older will be randomly assigned to receive either the new device or a s…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Custom-Made vaccine takes on untreated leukemia in early trial
Disease control Recruiting nowThis early-phase study tests a personalized neoantigen vaccine (NeoVax) in 15 people with untreated chronic lymphocytic leukemia (CLL) who have a specific genetic marker (IGHV unmutated). The vaccine is designed to train the immune system to attack each person's unique cancer cel…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could fewer stents mean better recovery after a heart attack?
Disease control Recruiting nowThis study compares a new approach using fewer stents and a drug-coated balloon to the standard method of placing stents in heart attack patients. About 1,272 participants will be randomly assigned to one of the two treatments. The goal is to see if the reduced-stent strategy low…
Phase: NA • Sponsor: Hospital Universitario La Fe • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for blood cancer patients: daily pill aims to prevent relapse without transplant
Disease control Recruiting nowThis study tests a daily pill called ivosidenib in about 20 adults with a specific genetic form of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who cannot receive a stem cell transplant. The goal is to see if the drug can keep the cancer from coming ba…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for tough leukemia? tiny trial tests targeted pill
Disease control Recruiting nowThis study tests an oral drug called olutasidenib in 3 Japanese patients whose acute myeloid leukemia (AML) has a specific IDH1 gene mutation and has not responded to or returned after other treatments. The main goal is to check safety, but researchers will also see if the drug c…
Phase: PHASE2 • Sponsor: Kissei Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New immune therapy aims to tackle tough childhood leukemia
Disease control Recruiting nowThis early-stage trial is testing a new type of immunotherapy for children and young adults with a high-risk or relapsed form of acute lymphoblastic leukemia. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack leukemia cells tha…
Phase: PHASE1 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New Clot-Busting drug could change heart attack care
Disease control Recruiting nowThis study compares two drugs given directly into the heart arteries during a heart attack: rhTNK-tPA, a clot dissolver, and tirofiban, a blood thinner. Researchers will enroll 300 patients with severe blockages to see which drug restores blood flow better and causes fewer bleedi…
Phase: PHASE4 • Sponsor: Henan Institute of Cardiovascular Epidemiology • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could more water save Kids' kidneys? new trial tests simple IV strategy
Disease control Recruiting nowThis study tests whether giving children with a severe E. coli infection extra fluids through an IV can prevent kidney failure. About 1,040 children aged 9 months to 21 years will take part. The goal is to see if this simple approach reduces the need for dialysis or long-term kid…
Phase: NA • Sponsor: University of Calgary • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Feeding tube breakthrough: enzyme device could ease digestion for pancreatitis patients
Disease control Recruiting nowThis study tests a device called RELiZORB that adds digestive enzymes directly to liquid food given through a feeding tube. It is for people who have trouble digesting food after pancreatitis. The goal is to see if it improves symptoms and quality of life. About 60 adults will ta…
Phase: PHASE3 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New stem cell transplant method aims to cut complications in young blood cancer patients
Disease control Recruiting nowThis pilot study tests a stem cell transplant method that removes specific immune cells (alpha/beta T cells and B cells) from the donor cells before transplant. The goal is to reduce the risk of graft-versus-host disease, a serious complication, while still allowing the transplan…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New pill combo aims to tackle tough leukemia
Disease control Recruiting nowThis study is testing a new targeted drug called crifortinib besylate (taken as a pill) combined with standard chemotherapy in adults who have just been diagnosed with acute myeloid leukemia (AML). The trial has two phases: first, finding the best dose, then testing it in a large…
Phase: PHASE1, PHASE2 • Sponsor: Sunshine Lake Pharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New antibiotic could shield blood cancer patients from deadly infections
Disease control Recruiting nowThis study is for people with blood cancers like leukemia who are getting chemotherapy or a stem cell transplant, which can cause very low white blood cell counts (neutropenia) for over a week. The goal is to see if the antibiotic eravacycline can prevent serious bacterial infect…
Phase: PHASE2 • Sponsor: West Virginia University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New scan could spot hidden scarring in heart and lungs before It's too late
Diagnosis Recruiting nowThis study tests a new radioactive tracer called 18F-FAPI-74 that may help detect scar tissue (fibrosis) in the heart and lungs earlier than current methods. Researchers will compare this new PET/CT scan to standard imaging in 210 adults with conditions like lung disease or heart…
Phase: PHASE3 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Diagnosis
Last updated Aug 18, 2026 00:00 UTC
-
AI tool could predict which hospitalized kids need urgent care
Diagnosis Recruiting nowThis study looks at whether a computer program called pediatric eCART can help doctors quickly identify children in the hospital who are at high risk of serious problems like cardiac arrest or sepsis. Researchers will compare data from before and after the tool was put into use, …
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Could a heart MRI replace invasive scans for some heart attacks?
Diagnosis Recruiting nowThis study explores whether performing a cardiac MRI (CMR) before the standard invasive coronary angiography (ICA) can accurately diagnose the cause of a suspected non-ST-elevation heart attack (NSTEMI). Currently, patients with NSTEMI often undergo an invasive angiogram, and if …
Sponsor: Region Stockholm • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
A wearable sensor might spot kidney danger before it strikes
Diagnosis Recruiting nowThis study tests whether a new monitoring device can predict acute kidney injury (AKI) in adults undergoing heart surgery or procedures using contrast dye. The device measures kidney function in real time through the skin after a fluorescent tracer is injected. Researchers will t…
Sponsor: China National Center for Cardiovascular Diseases • Aim: Diagnosis
Last updated Aug 08, 2026 00:03 UTC
-
Marathon runners and heart patients put a new troponin test to the ultimate challenge
Diagnosis Recruiting nowThis study tests whether a lab technique called polyethylene glycol (PEG) precipitation can tell the difference between a true heart attack and a harmless condition called macrotroponin, where troponin molecules clump together and falsely signal heart damage. Researchers will com…
Phase: NA • Sponsor: Technical University of Munich • Aim: Diagnosis
Last updated Jul 26, 2026 00:00 UTC
-
New blood test could cut ER wait times for heart attack suspicions
Diagnosis Recruiting nowThis study will test a new, more accurate blood test (Troponin T high-sensitivity Gen 6) to see if it helps doctors diagnose heart attacks faster. Researchers will compare emergency department visit data from 19,500 patients before and after the test is introduced. The goal is to…
Phase: NA • Sponsor: University of Edinburgh • Aim: Diagnosis
Last updated Jul 09, 2026 00:00 UTC
-
Blood test may spot lung risk in brain injury patients
Diagnosis Recruiting nowThis study looks at whether a simple blood test, called the fibrinogen-to-albumin ratio, can predict if someone with a traumatic brain injury will develop acute respiratory distress syndrome (ARDS), a serious lung condition. Researchers will measure these proteins in the blood of…
Sponsor: Tanta University • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
New genetic test aims to sharpen blood cancer diagnosis
Diagnosis Recruiting nowThis study looks at a new genetic test called Caris Chromoseq for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms). The test scans the entire genome to help classify the cancer and guide risk assessment. Researc…
Sponsor: Caris Science, Inc. • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Ultrasound may help doctors time lifesaving lung treatment for preterm infants
Diagnosis Recruiting nowThis study tests whether using a lung ultrasound score can help doctors decide when to give surfactant therapy to premature infants with respiratory distress syndrome. Surfactant is a substance that helps babies' lungs stay open, but giving it too late can reduce its benefit. The…
Phase: NA • Sponsor: Connecticut Children's Medical Center • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New PET scan tracer aims to spot blood cancers more clearly
Diagnosis Recruiting nowThis study is testing a new radioactive tracer called 68Ga-EV203 for PET/CT scans in people with blood cancers like multiple myeloma, lymphoma, and leukemia. The goal is to see how the tracer spreads in the body, how much radiation it gives off, and whether it can find tumors bet…
Phase: NA • Sponsor: Zhejiang Cancer Hospital • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
AI blood test could spot heart attacks faster
Diagnosis Recruiting nowThis study is testing whether artificial intelligence (AI) can predict or rule out a heart attack using data from standard blood tests. Researchers will analyze white blood cell properties from over 3,000 adults who come to the hospital with chest pain. The goal is to see if AI c…
Sponsor: RobotDreams GmbH • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
New PET scan tracer could spot hidden blood cancers
Diagnosis Recruiting nowThis early-phase trial is testing a new radioactive imaging agent called 64Cu-LLP2A to see if it can safely and clearly show blood cancers like multiple myeloma and lymphoma on PET/CT scans. The study includes healthy volunteers and patients with these cancers, including those wh…
Phase: EARLY_PHASE1 • Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Urine test may spot kidney danger early in septic shock
Diagnosis Recruiting nowThis study investigates whether a urine test called Nephrocheck can predict which patients with septic shock will develop severe acute kidney injury. The test measures two markers of kidney damage (TIMP2 and IGFBP7). Researchers will analyze data from previous studies involving a…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
AI breakthrough could spot hidden heart attacks in patients with tricky ECG patterns
Diagnosis Recruiting nowThis study is testing whether a computer program (machine learning) can help doctors diagnose severe heart attacks in patients who have a heart condition called left bundle branch block (LBBB). LBBB can hide the usual signs of a heart attack on an ECG, making it hard to tell if a…
Sponsor: Konya City Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
Prevention Recruiting nowThis study looks at whether a low dose of the antifungal drug liposomal amphotericin B can prevent serious fungal infections in adults with blood cancers or who have had stem cell transplants and have a prolonged low white blood cell count (neutropenia). The trial enrolls 30 pati…
Sponsor: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine • Aim: Prevention
Last updated Aug 15, 2026 00:00 UTC
-
Dental cleaning may ward off deadly transplant complication
Prevention Recruiting nowThis study tests whether a dental cleaning shortly after a stem cell transplant can prevent chronic graft-versus-host disease (GVHD), a common and serious complication. Researchers will enroll 45 adults receiving a donor stem cell transplant for blood cancer. The goal is to see i…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Can a gas added to Heart-Lung machines shield Newborns' kidneys?
Prevention Recruiting nowThis trial tests whether adding nitric oxide gas to the heart-lung machine during surgery can prevent acute kidney injury in newborns with congenital heart defects. Up to 60% of these babies experience kidney damage after surgery, which can lead to serious complications. The stud…
Phase: PHASE3 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
Could removing the gallbladder stop mystery pancreatitis attacks?
Prevention Recruiting nowThis trial tests whether removing the gallbladder with keyhole surgery can prevent repeat episodes of acute pancreatitis in people whose cause remains unknown after thorough testing. Half the participants will have the surgery, while the other half will receive watchful waiting. …
Phase: NA • Sponsor: M.G. Besselink • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
Chilled water may curb pancreatitis risk after Bile-Duct procedure
Prevention Recruiting nowThis trial tests whether rinsing the bile-duct opening with ice-cold water, on top of standard anti-inflammatory medication, can lower the chance of pancreatitis after an ERCP procedure. About 462 adults who need an ERCP will receive either the usual NSAID pill alone or the NSAID…
Phase: NA • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Prevention
Last updated Aug 01, 2026 00:00 UTC
-
Poop pills to prevent transplant rejection? new trial tests fecal transplants in blood cancer patients
Prevention Recruiting nowThis study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …
Phase: PHASE2 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Could a single drug shield kidneys during heart surgery?
Prevention Recruiting nowThis study tests whether the drug R2R01 can prevent acute kidney injury in people at high risk who are having heart surgery with a heart-lung machine. Participants receive either R2R01 or a placebo before and after surgery. The goal is to see if the drug reduces kidney damage and…
Phase: PHASE2 • Sponsor: River 2 Renal Corp. • Aim: Prevention
Last updated Jun 27, 2026 13:02 UTC
-
Heart patients get flu shot at discharge to prevent future attacks
Prevention Recruiting nowThis study tests whether giving the flu vaccine to heart patients just before they leave the hospital can lower their risk of infections, heart problems, and death in the next 6 months. About 400 adults hospitalized for serious heart conditions will be randomly assigned to get th…
Phase: PHASE4 • Sponsor: Wroclaw Medical University • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Earbud device could ease insomnia in childhood cancer survivors
Symptom relief Recruiting nowThis study tests whether a non-invasive earbud that gently stimulates a nerve in the ear can help adult survivors of childhood leukemia who have trouble sleeping. Forty participants will be randomly assigned to receive either active or sham stimulation nightly for 2 to 8 weeks. T…
Phase: NA • Sponsor: St. Jude Children's Research Hospital • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
New drug aims to cut short sickle cell pain attacks
Symptom relief Recruiting nowThis study tests an investigational drug called CSL889 in 70 adults and adolescents with sickle cell disease who are having a painful vaso-occlusive crisis. The goal is to see if the drug can safely shorten the crisis and reduce the need for strong pain medicines. Participants wi…
Phase: PHASE2 • Sponsor: CSL Behring • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Healing harmonies: music therapy aims to ease stem cell transplant recovery
Symptom relief Recruiting nowThis study tests an online music therapy program that combines mindfulness and music to help people recovering from stem cell transplants for blood cancers. Researchers want to see if it can improve quality of life, reduce pain, fatigue, anxiety, and depression, and possibly spee…
Phase: NA • Sponsor: University of Miami • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Talking about the end: could guided conversations reduce futile cancer treatments?
Symptom relief Recruiting nowThis trial tests a program called ACT, which trains doctors and nurses to have compassionate, structured conversations with blood cancer patients and their families about end-of-life care. The goal is to help patients understand their prognosis and make informed decisions, potent…
Phase: NA • Sponsor: Christoffer Johansen • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Magic mushroom therapy could help cancer survivors beat depression
Symptom relief Recruiting nowThis study tests whether psilocybin, the active ingredient in magic mushrooms, combined with talk therapy can safely help cancer survivors with depression or anxiety. Twenty adults who have finished cancer treatment and have no brain involvement will receive a single dose of psil…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
VR goggles and gentle brain zaps aim to ease war PTSD
Symptom relief Recruiting nowThis study tests whether combining virtual reality therapy with a mild brain stimulation technique can help veterans and civilians in Ukraine cope with PTSD. Participants attend 10 therapy sessions using VR goggles to safely face traumatic memories, with some also receiving a gen…
Phase: NA • Sponsor: Malek Bajbouj • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New oxygen method may speed recovery from High-Altitude lung condition
Symptom relief Recruiting nowThis study tests if a special high-flow oxygen mask works better than standard oxygen for people with high-altitude pulmonary edema (fluid in the lungs from climbing too high too fast). About 200 adults who develop symptoms within 7 days of reaching high altitude will be randomly…
Phase: NA • Sponsor: Third Military Medical University • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New study aims to find safer way to help preemies breathe
Symptom relief Recruiting nowThis study compares two methods of giving surfactant, a medicine that helps premature babies breathe. One method uses a thin tube, the other uses a small airway device. The goal is to see which method causes fewer breathing problems and complications in infants born at 29 weeks o…
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
New online therapy aims to ease PTSD after sexual abuse
Symptom relief Recruiting nowThis study tests a new anonymous online therapy program called Restory for people with PTSD after sexual abuse. It is designed for 140 adults who have experienced sexual violence at least one month ago. The therapy uses a type of talk therapy done over the internet, and the goal …
Phase: NA • Sponsor: Karolinska Institutet • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Brain training shows promise for PTSD in veterans
Symptom relief Recruiting nowThis study tests whether a computer-based working memory training program can help veterans with PTSD improve their ability to unlearn fear responses. 120 veterans will be randomly assigned to either the training or a sham version. The goal is to see if the training changes brain…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New devices aim to soothe sore throats without drugs
Symptom relief Recruiting nowThis study will test four medical devices (HMG, PHN, PHR, TUR) in 160 adults with sore throat from acute pharyngitis or viral tonsillitis. The goal is to see if they are safe and help reduce symptoms like pain when swallowing. Participants will use the device for up to 7 days and…
Phase: NA • Sponsor: University Hospital, Clermont-Ferrand • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Could a common cholesterol drug ease pancreatitis pain?
Symptom relief Recruiting nowThis pilot study tests whether simvastatin, a common cholesterol medication, can improve quality of life in adults with recurrent acute or chronic pancreatitis. Researchers will enroll 90 participants to check if the drug is feasible and acceptable. The goal is to see if it helps…
Phase: EARLY_PHASE1 • Sponsor: Cedars-Sinai Medical Center • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Exercise during chemo: new study tests strength training for children with leukemia
Symptom relief Recruiting nowThis study tests whether a 9-week strength training program using resistance bands and body weight exercises is practical for children aged 6-21 newly diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma. The program combines at-home exercises with optional Zoom …
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Can a psychedelic drug help heal trauma? a small trial puts psilocybin to the test
Symptom relief Recruiting nowThis early-stage pilot study is testing whether psilocybin, a psychedelic compound, can be safely combined with trauma-focused psychotherapy for people with post-traumatic stress disorder (PTSD). Thirteen participants will receive two doses of psilocybin in a controlled setting, …
Phase: EARLY_PHASE1 • Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Virtual nature walks could soothe heart attack patients in intensive care
Symptom relief Recruiting nowThis study tests whether watching nature videos through virtual reality glasses can lower anxiety and improve vital signs like heart rate and blood pressure in people recovering from a heart attack in the intensive care unit. Half of the 50 participants will use VR glasses for a …
Phase: NA • Sponsor: Yuzuncu Yil University • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Can a tailored exercise and diet plan beat cancer fatigue?
Symptom relief Recruiting nowThis study tests a personalized program combining exercise and nutrition advice to help reduce fatigue in people with indolent (slow-growing) lymphomas, such as chronic lymphocytic leukemia and follicular lymphoma. Participants receive an individualized exercise plan and dietary …
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Keyhole surgery debate: which exit wound is best for gallbladder removal?
Symptom relief Recruiting nowThis study compares two methods of removing the gallbladder during laparoscopic (keyhole) surgery: through a port near the belly button or one below the breastbone. The goal is to see which approach causes less pain and fewer wound problems like infection. The trial will involve …
Phase: NA • Sponsor: King Edward Medical University • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
New anxiety program for ICU survivors shows promise in early trial
Symptom relief Recruiting nowThis pilot study tests a self-management program based on cognitive behavioral therapy to help people who survived acute respiratory failure and now struggle with anxiety. Sixty ICU survivors will either receive the program or usual care. The goal is to see if the program is prac…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Virtual reality headsets bring peace to ICU patients
Symptom relief Recruiting nowThis study tests whether short, calming virtual reality (VR) sessions can safely reduce anxiety, agitation, and delirium in adult intensive care unit (ICU) patients. Thirty participants will watch nature-based VR content using a headset. The main goal is to see if this approach i…
Phase: NA • Sponsor: Milton S. Hershey Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Vitamin d pills put to the test against stress shocks
Symptom relief Recruiting nowThis study tests whether taking vitamin D daily for 8 weeks helps healthy adults keep their thinking, simple physical tasks, and mood steady during very stressful situations. 52 participants will take either vitamin D or a placebo, then perform tasks while wearing a belt that giv…
Phase: NA • Sponsor: Walter Reed Army Institute of Research (WRAIR) • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could a pacemaker for the vagus nerve ease PTSD?
Symptom relief Recruiting nowThis early study tests whether a surgically implanted device that stimulates the vagus nerve can boost the effects of talk therapy for people with chronic PTSD. Twenty adults who have not gotten better with standard treatments will receive either active or sham stimulation alongs…
Phase: NA • Sponsor: The University of Texas at Dallas • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Can talk therapy tame brain Injury's emotional storm?
Symptom relief Recruiting nowThis study tests whether dialectical behavior therapy (DBT), a type of talk therapy, can help people with acquired brain injury manage emotional distress and challenging behaviors. 77 participants will receive standard care for 5 months, then DBT for 5 months, then follow-up. Res…
Phase: NA • Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Could a bladder rinse make emergency kidney stone treatment easier?
Symptom relief Recruiting nowThis study tests whether putting a drug called aminophylline into the bladder before placing a ureteral stent helps doctors get the stent past a blocking stone more easily. The trial involves 72 adults with sudden kidney failure from stones in a single working kidney. Half get th…
Phase: PHASE2 • Sponsor: Beni-Suef University • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Scientists track rare gene variant to unlock blood disorder mysteries
Knowledge-focused Recruiting nowThis study follows people of all ages who have or may have a RUNX1 gene variant, which can cause bleeding problems and increase the risk of blood cancers. Researchers will collect medical history, blood samples, and bone marrow over many years to understand how the condition deve…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
New screening trial aims to speed up matching of cancer patients to the right treatments
Knowledge-focused Recruiting nowThis study tests a new way to screen patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by analyzing their bone marrow and blood for specific biomarkers. The goal is to quickly match patients with a treatment trial that targets their cancer's unique mark…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
New study aims to prevent lung collapse after surgery
Knowledge-focused Recruiting nowThis study tests a special method of removing the breathing tube after abdominal surgery to prevent lung problems. It involves 270 adults at moderate or high risk of lung complications. The goal is to see if a protective extubation approach is practical and followed correctly by …
Phase: NA • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists seek samples to build better Cancer-Killing drugs
Knowledge-focused Recruiting nowThis study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Can immune cells heal the heart and brain after attack?
Knowledge-focused Recruiting nowThis study looks at how certain white blood cells, called monocytes, react to injury from a heart attack or ischemic stroke. Researchers want to learn how these cells sense danger signals and produce substances that might help heart muscle and brain tissue heal. The study involve…
Sponsor: UConn Health • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Sickle cell study aims to uncover disease patterns
Knowledge-focused Recruiting nowThis study follows up to 3,500 people with sickle cell disease to learn more about how the condition progresses and what complications arise. Participants receive their usual medical care outside the hospital and visit the clinic for check-ups and research tests. No experimental …
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Smart testing after CAR t: could it spare kids from unneeded transplants?
Knowledge-focused Recruiting nowThis study tests whether regular blood and bone marrow tests using advanced DNA sequencing can better monitor children with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission with CAR T therapy. The goal is to see if these tests can identify who is truly cur…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
AI may foresee lung complications after liver surgery
Knowledge-focused Recruiting nowThis study aims to build a digital early-warning system that uses machine learning to predict acute lung injury (ALI) in patients undergoing major liver surgery. By analyzing cardiopulmonary interaction characteristics, the model could help doctors identify at-risk patients early…
Sponsor: Beijing Tsinghua Chang Gung Hospital • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Blood test clues: could two proteins predict heart failure after a heart attack?
Knowledge-focused Recruiting nowThis study looks at whether two proteins released when heart muscle is damaged can be detected in the blood during a heart attack. Researchers want to see if higher levels of these proteins are linked to a greater chance of developing heart failure afterward. The study includes a…
Sponsor: UConn Health • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Can immune cells predict how well the heart heals after an attack?
Knowledge-focused Recruiting nowThis study investigates whether the types and behavior of certain immune cells (neutrophils and monocytes) in the blood are linked to how the heart repairs itself after a heart attack. Researchers will follow 50 adults who have had a severe type of heart attack and are scheduled …
Sponsor: Shanghai 10th People's Hospital • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
New blood test could spot pancreatic cancer sooner
Knowledge-focused Recruiting nowThis study aims to create a simple, minimally invasive test to find pancreatic cancer at an early stage and track how well treatment is working. Researchers will study 700 people with pancreatic cancer, pancreatitis, or pancreatic cysts. The goal is to identify biological markers…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
How does venetoclax work for CLL patients in everyday clinics?
Knowledge-focused Recruiting nowThis study is tracking 500 people with chronic lymphocytic leukemia (CLL) who are taking venetoclax, either alone or with other drugs, as part of their normal care in Austria, Germany, and Switzerland. Researchers want to see how well the treatment works in real-life settings and…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Massive study to track what happens when AML comes back
Knowledge-focused Recruiting nowThis observational study will follow 4,000 people whose acute myeloid leukemia has returned or not responded to treatment. Researchers will collect data from routine care to understand survival rates and treatment patterns over up to 4 years. No new drugs are being tested; the go…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
New pilot study aims to improve leukaemia treatment for young patients
Knowledge-focused Recruiting nowThis pilot study is for children and young adults (0-45 years) newly diagnosed with acute lymphoblastic leukaemia (ALL). It collects information on standard treatments already used in clinics to help prepare for future research trials. The study involves 500 participants and focu…
Sponsor: Mats Heyman • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Could a quick CPAP boost help preterm babies breathe better?
Knowledge-focused Recruiting nowThis study tests whether briefly increasing the air pressure from a CPAP machine before giving surfactant therapy helps preterm babies' lungs work better. Surfactant is a natural substance that helps immature lungs stay open, and it's often given through a thin tube. The trial wi…
Phase: NA • Sponsor: Murdoch Childrens Research Institute • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Simple blood test could predict transplant complications
Knowledge-focused Recruiting nowThis study looks at a new method to measure special immune cells called iNKT cells in the blood of patients who have had a stem cell transplant. These cells may help predict serious complications like graft-versus-host disease (GvHD) and relapse. Researchers will test 75 adults w…
Sponsor: University Hospital Pilsen • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
Knowledge-focused Recruiting nowThis study follows 1,500 people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases — rare conditions where the virus drives abnormal immune cell growth. Researchers will collect medical history, treatment details, and blood samples to see how the diseases beh…
Sponsor: Rong Tao • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Frailty check may steer safer cancer care for seniors
Knowledge-focused Recruiting nowThis study looks at whether simple frailty assessments can predict how older patients (60+) with acute leukemia or MDS will fare after intensive treatments like chemotherapy, CAR T-cell therapy, or stem cell transplants. Researchers will track frailty status and compare outcomes …
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
CLL drug venetoclax under the microscope: genetic clues may improve treatment
Knowledge-focused Recruiting nowThis study tracks genetic changes in chronic lymphocytic leukemia (CLL) cells during treatment with the drug venetoclax. Researchers aim to understand how the cancer evolves as the drug is started. 75 adults with relapsed or refractory CLL will receive venetoclax and undergo regu…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
A simple blood test may reveal hidden infertility risk in young cancer survivors
Knowledge-focused Recruiting nowThis study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …
Sponsor: Erasme University Hospital • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Coin flip chemo: study tests if patients will let a computer choose their treatment strength
Knowledge-focused Recruiting nowThis study looks at whether adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy are willing to let a computer randomly assign them to either lower- or higher-intensity treatment. The goal is to see if this approach is acceptable to patients…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New combo test aims to spot hidden heart risk after attack
Knowledge-focused Recruiting nowThis study looks at whether combining a new type of CT scan with a blood test for tiny molecules called microRNAs can better predict heart damage after a heart attack. Researchers will follow 95 patients who had a severe heart attack and measure changes in their heart size over s…
Phase: NA • Sponsor: Instituto de Investigación Biomédica de Salamanca • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New device for leg clots tested in first human survey
Knowledge-focused Recruiting nowThis study surveys doctors who use the Liberant system to remove fresh blood clots from leg arteries and veins. About 50 patients aged 22 or older will be treated within 72 hours of their procedure. The goal is to confirm the device is safe and works as intended.
Sponsor: Medtronic Endovascular • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New study checks if cancer drug olutasidenib changes how other medicines work
Knowledge-focused Recruiting nowThis study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…
Phase: PHASE4 • Sponsor: Rigel Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Scientists to decode why common cold turns severe in kids
Knowledge-focused Recruiting nowThis study aims to find out how often rhinovirus (the virus behind many common colds) causes serious breathing problems that require hospital care in children. Researchers will follow 120 young children at home for 3 years and study 450 hospitalized infants and children, plus 100…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
AI platform aims to unlock Real-World cancer data on a massive scale
Knowledge-focused Recruiting nowThis study enrolls people diagnosed with cancer to build a large registry using Olivia, an AI-powered health platform. The platform will collect and combine electronic health records and patient-reported outcomes from over 1,000 healthcare systems. The goal is to create a compreh…
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Which ventilator mode is best for heart patients? a pilot study aims to find out
Knowledge-focused Recruiting nowThis study tests whether it is possible to run a larger trial comparing two ways of using a breathing machine (ventilator) in critically ill heart patients who need help breathing. The two modes are volume-controlled (delivers a set amount of air each breath) and pressure-control…
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can we make CAR-T cells last longer in leukemia?
Knowledge-focused Recruiting nowThis study follows children and young adults with acute lymphoblastic leukemia (ALL) who receive CAR-T cell therapy. The goal is to track how long these engineered immune cells persist in the body and identify factors that cause them to disappear. By understanding why CAR-T cells…
Sponsor: University College, London • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Which intubation timing is best for breathing failure? new study aims to find out
Knowledge-focused Recruiting nowThis study looks at two different approaches to deciding when to place a breathing tube in patients with acute hypoxemic respiratory failure (dangerously low oxygen levels). One strategy is more liberal (intubate earlier to prevent complications from low oxygen), while the other …
Phase: NA • Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Heart risk from leukemia drugs under the microscope
Knowledge-focused Recruiting nowThis study watches people with blood cancers like CLL who take BTK inhibitors or venetoclax to see how these drugs affect heart rhythm. Researchers will use EKGs, stress tests, and heart monitors to track abnormal rhythms and sudden death risk. The goal is to better understand an…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New iPad tool aims to boost kidney injury awareness in kids
Knowledge-focused Recruiting nowThis study tests an interactive iPad educational tool to help families of children with acute kidney injury (AKI) learn more about the condition. Researchers will measure AKI knowledge before and one month after using the tool. The goal is to improve patient-centered care and red…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Blood test may personalize leukemia drug dosing
Knowledge-focused Recruiting nowThis study looks at whether measuring the amount of venetoclax in the blood can help doctors give the right dose to people with newly diagnosed acute myeloid leukemia (AML). Currently, everyone gets the same dose, but drug levels vary a lot between patients. The goal is to find a…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can we predict lung failure in children by measuring their breathing effort?
Knowledge-focused Recruiting nowThis study investigates whether measuring the physical effort of breathing in children with acute respiratory distress syndrome (ARDS) can predict how the disease will progress. Researchers will use advanced, non-invasive monitoring tools to track breathing drive, effort, and lun…
Sponsor: Universidad Nacional Andres Bello • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Scientists launch major study to unravel mysteries of rare brain infection PML
Knowledge-focused Recruiting nowThis study follows 700 people with progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. Researchers will collect blood, spinal fluid, and brain scans over time to understand how the disease progresses. No treatment is given; the goal is…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
2000 volunteers help create a gold standard for cancer blood tests
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Massive blood cancer registry aims to unlock secrets of adult ALL
Knowledge-focused Recruiting nowThis study is a large registry that will collect medical information and biological samples from up to 10,000 adults with acute lymphoblastic leukemia (ALL) and related blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time. By gather…
Sponsor: Goethe University • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Blood cancer Patients' vaccine response under the microscope
Knowledge-focused Recruiting nowThis study looks at how well vaccines for flu, COVID-19, shingles, hepatitis B, and pneumonia work in people with certain blood cancers like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas. Researchers will measure immune responses through blood samples before and af…
Phase: PHASE4 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Lying left or right? study tests best position for ARDS recovery
Knowledge-focused Recruiting nowThis study looks at how lying on your left side, right side, or back affects lung function in adults with acute respiratory distress syndrome (ARDS) after abdominal surgery. Researchers will use a special imaging technique called electrical impedance tomography to measure how wel…
Phase: NA • Sponsor: Ruijin Hospital • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Massive european study aims to redefine success in liver transplants
Knowledge-focused Recruiting nowThis study is collecting information from 10,000 liver transplant patients across Europe to create a new, up-to-date reference for what good outcomes look like when using machine perfusion (a technique that keeps donated livers healthier before transplant). The goal is to help do…
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Can a simple blood test unlock the secrets of brain autoimmune diseases?
Knowledge-focused Recruiting nowThis study aims to discover biological markers (biomarkers) that could help doctors diagnose and track neurological autoimmune diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barre syndrome. Researchers will analyze samples from 50,000 people, including patie…
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Rare brain infection risk under scrutiny for multiple sclerosis drug ozanimod
Knowledge-focused Recruiting nowThis study investigates whether the multiple sclerosis medication ozanimod is linked to a higher risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection caused by the John Cunningham virus. Researchers will review reported cases of PML in peop…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
New PET scan may predict heart failure risk after heart attack
Knowledge-focused Recruiting nowThis study explores whether a special PET/MR scan can detect early signs of heart muscle damage after a heart attack. Researchers will scan 25 adults about 10 days after their heart attack and then track their heart function with MRI scans at 3 and 6 months. The goal is to see if…
Sponsor: Ankara University • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Can a simple social check improve leukemia care?
Knowledge-focused Recruiting nowThis study looks at whether screening adults with leukemia for social needs (like housing or food) and offering early social work help is practical and helpful. About 80 newly diagnosed patients will either get the screening and consultation or usual care. The goal is to see if t…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Can safer lung scans replace CT in infants? a study puts three methods to the test
Knowledge-focused Recruiting nowThis study compares three ways to image the lungs of infants: CT scans, electrical impedance tomography (EIT), and lung ultrasound. The goal is to see how well the non-invasive methods (EIT and ultrasound) match up with CT in detecting collapsed or overinflated lung areas. Ten in…
Sponsor: Medical University of Vienna • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Can daily CBD reshape your stress response? a study puts it to the test.
Knowledge-focused Recruiting nowThis study investigates whether people who use cannabidiol (CBD) regularly react differently to acute stress compared to those who do not. Healthy adults aged 21–70 who either use CBD daily or not at all will undergo a series of stressful tasks — including public speaking, mental…
Phase: NA • Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
Knowledge-focused Recruiting nowThis study follows 400 people in Norway with multiple myeloma, plasma cell leukemia, or AL amyloidosis who are receiving newer immunotherapies like teclistamab, elranatamab, or CAR-T cell therapy outside of clinical trials. Researchers will track how well these treatments control…
Sponsor: St. Olavs Hospital • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Gene mapping of childhood blood cancers could unlock personalized treatments
Knowledge-focused Recruiting nowThis research study collects and analyzes blood and bone marrow samples from children and young adults with leukemia, myelodysplastic syndrome, or myeloproliferative syndrome. By reading the genetic instructions in these cancer cells, scientists hope to understand why the disease…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New web tool aims to help families navigate tough choices on home ventilation for children
Knowledge-focused Recruiting nowThis study tests a web-based decision-support tool designed to help families and doctors make shared decisions about whether a child should go on chronic home ventilation. Half of the participating families use the tool, while the other half receive usual care. Researchers then m…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Hidden scars of childhood cancer: new imaging reveals heart and lung damage years after treatment
Knowledge-focused Recruiting nowThis study investigates the long-term heart and lung health of adults who survived childhood acute lymphoblastic leukemia (ALL) or lymphoma. Researchers use advanced MRI and other imaging to detect subtle damage from past chemotherapy, comparing survivors to healthy volunteers. T…
Phase: NA • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Blood test could spot deadly pancreatic infection earlier
Knowledge-focused Recruiting nowThis study aims to find new blood-based markers that can predict or diagnose infected pancreatic necrosis (IPN) in people with severe pancreatitis. About 20% of acute pancreatitis cases develop tissue death (necrosis), and when that tissue gets infected, the risk of death rises t…
Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Scientists hunt for hidden ARDS subtypes to crack deadly lung failure
Knowledge-focused Recruiting nowThis study will analyze samples from 130 ICU patients with ARDS (a severe lung injury) to better understand why the condition varies so much between people. Researchers will examine lung fluid, blood, and CT scans to identify distinct biological subtypes. The goal is not to test …
Sponsor: Medical University of Vienna • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
New surveillance study aims to spot respiratory outbreaks before they spread
Knowledge-focused Recruiting nowThis study tracks respiratory infections in thousands of patients across China to build a better early warning system. Researchers collect routine medical data and samples to identify which germs are circulating and how the body responds. The goal is to help hospitals and health …
Sponsor: Huashan Hospital • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
New study aims to personalize ventilator settings for lung injury patients
Knowledge-focused Recruiting nowThis study looks at two different methods for setting the pressure on a breathing machine (ventilator) in people with a serious lung condition called ARDS. The goal is to see which method improves oxygen levels better over 24 hours. About 52 adults with moderate to severe ARDS wi…
Phase: NA • Sponsor: Hospital Dr. Franco Ravera Zunino • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
New study aims to predict dialysis danger in ICU patients
Knowledge-focused Recruiting nowThis study will observe 128 critically ill patients with acute kidney injury who need dialysis to remove excess fluid. Researchers want to understand why some patients become unstable during fluid removal. They will monitor heart function, blood flow, and other signs before and d…
Sponsor: Hospital Las Higueras • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Smarter ventilator monitoring could prevent lung injury in ICU patients
Knowledge-focused Recruiting nowThis study tests whether advanced monitoring of breathing patterns can help prevent lung damage in intensive care unit (ICU) patients who need a ventilator for reasons other than lung failure, such as coma or sepsis. Researchers will use special sensors to track airway pressure, …
Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Tape measure or laser? study tests which height method best protects ARDS lungs
Knowledge-focused Recruiting nowThis study looks at how different ways of measuring height affect ventilator settings and lung injury risk in people with acute respiratory distress syndrome (ARDS). Researchers will measure 39 patients' heights using five methods (stadiometer, visual estimation, tape, laser, and…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Real-World watch on ph+ leukemia treatments aims to uncover best paths to remission
Knowledge-focused Recruiting nowThis study follows adults aged 18 and older who have a specific type of acute lymphoblastic leukemia (Ph+ ALL) and are receiving a combination of targeted drugs (BCR::ABL1 inhibitors) along with chemotherapy, steroids, or antibody therapy. Researchers will track how long patients…
Sponsor: Versailles Hospital • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
New registry aims to unlock secrets of rare leukemia
Knowledge-focused Recruiting nowThis study creates a registry for people with hairy cell leukemia (HCL), a rare form of adult leukemia. Researchers will track disease course, treatments, infections, and patient-reported outcomes over time. The goal is to identify trends, improve care, and design future clinical…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Tiny tube reveals how much oxygen really reaches preterm lungs
Knowledge-focused Recruiting nowThis study looks at preterm infants who need breathing support from a machine called nasal CPAP. Researchers want to find out how much oxygen actually reaches the baby's lungs by placing a small tube in the back of the mouth and using soft bands around the chest to measure lung e…
Phase: NA • Sponsor: University of Arkansas • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Video link to doctor may boost paramedic safety for kids in crisis
Knowledge-focused Recruiting nowThis study tests whether a live video connection between paramedics and pediatric emergency doctors improves care for critically ill children. Paramedics will treat infant mannequins in simulated ambulance scenarios, with some getting video support and others only audio. The goal…
Phase: NA • Sponsor: Boston Medical Center • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Lab-Grown lymph node model reveals how CLL cells resist treatment
Knowledge-focused Recruiting nowThis study investigates how chronic lymphocytic leukemia (CLL) cells change their energy use when they are in the lymph node environment, which may help them resist standard treatments. Researchers are building a lab model using patient leukemia cells and normal lymph node cells …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New registry aims to unlock secrets of cancer in older adults
Knowledge-focused Recruiting nowThis research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Blood bank aims to predict leukemia risk in MDS patients
Knowledge-focused Recruiting nowThis study gathers blood and bone marrow samples from 150 adults with myelodysplastic syndrome (MDS), a blood disorder that can turn into acute leukemia. Researchers want to find biological markers that help predict which patients are likely to progress to leukemia. The goal is t…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Massive heart attack data collection launches in tomsk
Knowledge-focused Recruiting nowThis study is a registry that collects information from all suspected heart attack cases in Tomsk, Russia. It aims to track how many people die within 28 days and one year after a heart attack. No new treatments or drugs are being tested—just observation and data gathering.
Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New index aims to better measure bile duct infection treatment outcomes
Knowledge-focused Recruiting nowThis study looks at medical records of 514 adults in India with acute cholangitis (a bile duct infection and blockage) who had a drainage procedure. The goal is to create a new composite index that combines factors like death, need for organ support, ICU stay, complications, hosp…
Sponsor: Asian Institute of Gastroenterology, India • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Nerve block injection may improve sleep for PTSD sufferers
Knowledge-focused Recruiting nowThis study looks at how a stellate ganglion block injection affects sleep in U.S. service members and veterans with PTSD who are already receiving talk therapy. About 40 participants will wear an EEG headband for three nights before and three nights after the injection to measure…
Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists build a biobank to crack the mystery of CAR-T cell failure
Knowledge-focused Recruiting nowThis study collects extra blood and bone marrow samples from people receiving CAR-T cell therapy for lymphoma or acute lymphoblastic leukemia. The goal is to build a biobank that researchers can use to investigate why about half of patients do not respond to this treatment. Parti…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study investigates why some AML patients face early bleeding or clotting risks
Knowledge-focused Recruiting nowThis observational study examines a specific group of patients with a type of acute myeloid leukemia (AML) that has an NPM1 mutation. Researchers want to see if a particular subset, called APL-like, is linked to early blood vessel problems like bleeding or clots. The study will l…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study tracks pregnancy in women with neuroimmune diseases
Knowledge-focused Recruiting nowThis study follows 100 women with neuroimmune diseases (like multiple sclerosis or myasthenia gravis) through pregnancy and up to five years after. Researchers will track disease activity, pregnancy complications, and baby health to learn how these conditions affect fertility and…
Sponsor: Third Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
VA launches study to get more heart patients into rehab
Knowledge-focused Recruiting nowThis study tests whether a new referral program helps more Veterans with heart conditions get into cardiac rehabilitation. Researchers will compare referral and attendance rates before and after the program starts at three VA hospitals, involving 816 participants over 12 months. …
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Emergency surgery outcomes under the microscope: what happens to patients?
Knowledge-focused Recruiting nowThis study reviews medical records from 3,000 patients who had emergency surgery at a Swedish hospital between 2009 and 2019. Researchers want to understand what factors increase risks and how patients fare in the long run, including complications, repeat surgeries, and survival.…
Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can lab tests guide better AML treatment choices?
Knowledge-focused Recruiting nowThis study explores whether combining a drug sensitivity test with detailed genetic profiling can help doctors recommend the best treatment for each patient with relapsed or refractory acute myeloid leukemia (AML). Researchers will take extra blood or bone marrow samples from 18 …
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study uses advanced scans to map brain inflammation over time
Knowledge-focused Recruiting nowThe CLUE study is a research project that follows 1,000 people with neuroinflammatory diseases like multiple sclerosis and neuromyelitis optica. Participants undergo detailed MRI and PET scans at the start and after one year to see how their brain, spinal cord, and optic nerves c…
Sponsor: Beijing Tiantan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood sugar swings after a heart attack may reveal hidden dangers
Knowledge-focused Recruiting nowThis study investigates whether blood sugar patterns, measured continuously with a wearable sensor, can predict serious heart problems in the year following a heart attack. Researchers will enroll 850 people hospitalized with acute coronary syndrome and track their glucose levels…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Scientists hunt for clues to improve leukemia treatment after transplant
Knowledge-focused Recruiting nowThis study looks at blood cells from 20 adults with acute myeloid leukemia (AML) whose cancer returned after a stem cell transplant. All participants have specific genetic changes (NPM1 mutations or KMT2A rearrangements) and are being treated with a menin inhibitor. Researchers w…
Sponsor: University of Freiburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Can a simple Oxygen-Weaning protocol keep breathing patients off the ventilator?
Knowledge-focused Recruiting nowThis study compares a step-by-step protocol for stopping high-flow nasal oxygen therapy against usual doctor-led care in 148 adults with acute respiratory failure. The protocol uses oxygen levels and breathing rate to decide when to stop. The goal is to see if a standard approach…
Phase: NA • Sponsor: University of Milan • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Leukemia drug study probes thinking and memory side effects
Knowledge-focused Recruiting nowThis study looks at whether targeted cancer drugs called TKIs affect brain health and well-being in people with chronic leukemia. Researchers will compare 400 patients who receive TKI therapy to those who do not. The goal is to understand if these treatments cause cognitive chang…
Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Lab study hopes to unlock ARDS treatment using patient blood cells
Knowledge-focused Recruiting nowThis study looks at blood from people with ARDS, a severe lung condition with no specific medicines. Researchers will take immune cells from the blood and test a new blocking agent in the lab to see if it can reduce lung damage. The goal is to learn more about the disease and fin…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Blood test may predict who needs a breathing tube
Knowledge-focused Recruiting nowThis observational study with 300 ICU patients aims to see if combining blood markers (metabolomics) with standard clinical data can better predict when high-flow nasal cannula fails, requiring a breathing tube. Researchers will collect blood samples and monitor outcomes to build…
Sponsor: Hospital del Mar Research Institute (IMIM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Scientists decode immune clues to improve leukemia treatment
Knowledge-focused Recruiting nowThis study collects blood and bone marrow samples from 80 adults newly diagnosed with acute myeloid leukemia (AML). Researchers will measure inflammasome activity before and after standard chemotherapy to see if it relates to how well the treatment works. The goal is to better un…
Sponsor: Ciceri Fabio • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New monitoring methods could protect kidneys during surgery
Knowledge-focused Recruiting nowThis study watches how blood flows to the kidneys in 51 adults having elective minimally invasive abdominal surgery. Researchers use two non-invasive tools—ultrasound and light sensors—to measure kidney function at key times during and after surgery. The goal is to see if these t…
Sponsor: Istanbul University - Cerrahpasa • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Massive global study aims to uncover why young cancer patients in poorer nations fare worse
Knowledge-focused Recruiting nowThis study will follow 6,000 children, adolescents, and young adults with cancer in low- and middle-income countries. Researchers will collect data from medical records and questionnaires to understand why treatment failure and severe side effects are more common in these setting…
Sponsor: Resonance, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Heart attack survivors get a secret weapon: a mini monitor that spots hidden danger
Knowledge-focused Recruiting nowAfter a heart attack, patients face a high risk of dangerous heart rhythms, but current monitoring methods may miss them. This trial tests whether a small implantable cardiac monitor (ICM) placed under the skin can catch these rhythms earlier and help doctors adjust treatment. Tw…
Phase: NA • Sponsor: Samir Saba • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Could a common anesthetic gas help ICU patients breathe better on ventilators?
Knowledge-focused Recruiting nowThis study looks at how different sedatives affect the breathing of patients with acute respiratory distress syndrome (ARDS) who are on a ventilator. Twenty adults in the ICU will receive both standard intravenous propofol and inhaled isoflurane (a gas used in anesthesia) for sho…
Phase: PHASE2, PHASE3 • Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Pneumonia's hidden heart risk: new study tracks Long-Term damage
Knowledge-focused Recruiting nowThis study follows 300 people who had hospital-acquired pneumonia to see how it affects their heart and lungs over 18 months. Researchers will take blood samples, swabs, and perform heart and lung tests to understand the link between pneumonia and later cardiovascular problems li…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Protein puzzle: can diet help kidneys recover in the ICU?
Knowledge-focused Recruiting nowThis study looks at whether giving more protein (over 1.2 grams per kilogram per day) to critically ill patients with acute kidney injury helps their kidneys recover faster or causes harm. Researchers will review medical records from 344 adults in five Argentine ICUs, comparing t…
Sponsor: Hospital Italiano de Buenos Aires • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
2000 coma patients tracked to unlock recovery secrets
Knowledge-focused Recruiting nowThis study follows 2000 adults who are in a coma or have disorders of consciousness after serious brain injuries like stroke, cardiac arrest, or trauma. Researchers collect medical records and later interview survivors or their caregivers about physical and emotional recovery. No…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Can what kids eat during cancer treatment change outcomes? new study aims to find out
Knowledge-focused Recruiting nowThis study follows 1,400 children and teens (ages 3-21) in Southern Europe with acute lymphoblastic leukemia or certain brain tumors. Researchers will track their diet, lifestyle, and quality of life over time to see how these factors relate to treatment side effects and survival…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Simple chest squeeze may replace High-Tech ventilator settings
Knowledge-focused Recruiting nowThis study tests whether a simple manual chest compression technique works as well as electrical impedance tomography (a special imaging method) to find the best ventilator pressure for people with acute respiratory distress syndrome (ARDS). Thirty adults on ventilators will have…
Phase: NA • Sponsor: Centre Hospitalier Saint Joseph Saint Luc de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Estonian ICUs join forces to uncover hidden gut crisis
Knowledge-focused Recruiting nowThis study is watching 150 ICU patients in Estonia who doctors suspect have acute mesenteric ischemia, a rare but deadly gut condition. Researchers will track medical records, lab results, and CT scans to find clues that predict severe bowel damage. No new treatments are being te…
Sponsor: University of Tartu • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Can heart health predict ventilator weaning success?
Knowledge-focused Recruiting nowThis study looks at whether the heart's pumping ability plays a role in why some patients fail to come off a mechanical ventilator. Researchers will use ultrasound to check heart and lung function before and during a breathing test in 250 intensive care patients. The goal is to b…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New study aims to catch transplant complications early with blood and urine tests
Knowledge-focused Recruiting nowThis study is looking at 1,000 liver transplant recipients to see if testing their blood, urine, and tissue samples can detect early signs of chronic kidney disease, acute rejection, or hepatitis C. The goal is to find simple biomarkers that could lead to earlier treatment and fe…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Flu shot study probes hidden inflammation clues in High-Risk patients
Knowledge-focused Recruiting nowThis study looks at 60 adult male smokers under 65 who have both heart disease (acute coronary syndrome) and pneumonia along with COPD. Researchers want to see if certain blood markers (GDF-15, MR proADM, and Presepsin) change after getting a flu shot. The goal is to understand h…
Phase: PHASE3 • Sponsor: University of Brawijaya • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Scientists hunt for hidden antibodies in severe seizure disorders
Knowledge-focused Recruiting nowThis study collects blood, spinal fluid, and brain tissue from 400 people with severe seizures (status epilepticus) or epilepsy linked to brain inflammation (dysimmune encephalitis), plus control patients. Researchers aim to find antibodies and markers of nerve cell death that co…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Heart scans reveal best breathing test for ICU patients
Knowledge-focused Recruiting nowThis study looks at 24 ICU patients on breathing machines who are ready to try breathing on their own. Doctors will use heart ultrasound to see which of three breathing tests is easiest on the heart. The goal is to find the best way to help patients safely stop using the breathin…
Phase: NA • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New web app aims to close gaps in leukemia care
Knowledge-focused Recruiting nowThis study is testing a web-based tool called TRIAL that provides information and resources about acute leukemia and clinical trials. Researchers want to see if the tool is easy to use and if people will complete the surveys. About 75 English-speaking adults with suspected acute …
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Can a smartphone app keep you on track after rehab?
Knowledge-focused Recruiting nowThis study tests a digital lifestyle platform designed to support patients after they leave inpatient rehabilitation. It includes people with COPD, heart problems, fractures, or minor stroke. Participants use the platform for six months, receiving personalized recommendations and…
Phase: NA • Sponsor: Matthias Wilhelm, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Massive global registry aims to predict heart damage from cancer therapy
Knowledge-focused Recruiting nowThis study is a worldwide registry that follows 5,000 adults with breast cancer, blood cancers, or those on immune checkpoint inhibitors. Researchers collect medical records, lab results, and imaging to identify who is at risk for heart problems during or after cancer treatment. …
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Blood test may forecast heart failure risk after heart attack
Knowledge-focused Recruiting nowThis study is looking for clues in the blood that could predict if a person's heart will change shape or develop serious problems after a major heart attack. Researchers will collect blood samples and perform heart ultrasounds on 1,000 patients over six months. The goal is to fin…
Sponsor: Beijing Anzhen Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC